Descriptor: "COVID-19 (Malaltia) - Tractament" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"COVID-19 (Malaltia) - Tractament"' showing total 24 results

Start Over Descriptor "COVID-19 (Malaltia) - Tractament"

24 results on '"COVID-19 (Malaltia) - Tractament"'

1. Oxygen Consumption with High-Flow Nasal Oxygen versus Mechanical Ventilation- An International Multicenter Observational Study in COVID-19 Patients (PROXY-COVID)

Author: Botta, Michela, Caritg, Oriol, van Meenen, David M. P., Pacheco, Andrés, Tsonas, Anissa M., Mooij, Willemijn E., Burgener, Alessia, Manrique Hehl, Tosca, Shrestha, Gentle S., Horn, Janneke, Tuinman, Pieter R., Paulus, Frederique, Roca, Oriol, Schultz, Marcus J., Graduate School, Intensive Care Medicine, Anesthesiology, 06 Operations Centre and intensive care, ACS - Pulmonary hypertension & thrombosis, AII - Infectious diseases, AII - Inflammatory diseases, ARD - Amsterdam Reproduction and Development, ANS - Neuroinfection & -inflammation, Nursing, ACS - Diabetes & metabolism, ACS - Microcirculation, Intensive care medicine, Institut Català de la Salut, [Botta M, van Meenen DMP, Tsonas AM, Mooij WE] Department of Intensive Care, Amsterdam University Medical Centers, location AMC, Amsterdam, The Netherlands. [Caritg O, Pacheco A] Servei de Medicina Intensiva, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Roca O] Department of Intensive Care, Parc Taulí de Sabadell University Hospital, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Ciber Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Therapeutics::Airway Management::Respiration, Artificial [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Infectious Diseases, COVID-19 (Malaltia) - Tractament, terapéutica::manejo de la via aérea::respiración artificial [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Virology, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Metabolism::Oxygen Consumption [PHENOMENA AND PROCESSES], Parasitology, Oxigen, metabolismo::consumo de oxígeno [FENÓMENOS Y PROCESOS], Respiració artificial
Abstract: The COVID–19 pandemic led to local oxygen shortages worldwide. To gain a better understanding of oxygen consumption with different respiratory supportive therapies, we conducted an international multicenter observational study to determine the precise amount of oxygen consumption with high-flow nasal oxygen (HFNO) and with mechanical ventilation. A retrospective observational study was conducted in three intensive care units (ICUs) in the Netherlands and Spain. Patients were classified as HFNO patients or ventilated patients, according to the mode of oxygen supplementation with which a patient started. The primary endpoint was actual oxygen consumption; secondary endpoints were hourly and total oxygen consumption during the first two full calendar days. Of 275 patients, 147 started with HFNO and 128 with mechanical ventilation. Actual oxygen use was 4.9-fold higher in patients who started with HFNO than in patients who started with ventilation (median 14.2 [8.4–18.4] versus 2.9 [1.8–4.1] L/minute; mean difference = 11.3 [95% CI 11.0–11.6] L/minute; P < 0.01). Hourly and total oxygen consumption were 4.8-fold (P < 0.01) and 4.8-fold (P < 0.01) higher. Actual oxygen consumption, hourly oxygen consumption, and total oxygen consumption are substantially higher in patients that start with HFNO compared with patients that start with mechanical ventilation. This information may help hospitals and ICUs predicting oxygen needs during high-demand periods and could guide decisions regarding the source of distribution of medical oxygen.
Published: 2023

2. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

Author: Beatriz Mateos-Muñoz, María Buti, Inmaculada Fernández Vázquez, Marta Hernández Conde, Vanesa Bernal-Monterde, Fernando Díaz-Fontenla, Rosa María Morillas, Luisa García-Buey, Ester Badía, Mireia Miquel, Alberto Amador-Navarrete, Sergio Rodríguez-Tajes, Lucía Ramos-Merino, Antonio Madejón, Montserrat García-Retortillo, Juan Ignacio Arenas, Joaquín Cabezas, Jesús Manuel González Santiago, Conrado Fernández-Rodríguez, Patricia Cordero, Moisés Diago, Antonio Mancebo, Alberto Pardo, Manuel Rodríguez, Elena Hoyas, Jose Javier Moreno, Juan Turnes, Miguel Ángel Simón, Cristina Marcos-Fosch, Jose Luis Calleja, Rafael Bañares, Sabela Lens, Javier Garcia-Samaniego, Javier Crespo, Manuel Romero-Gomez, Francisco Gea, Enrique Rodríguez de Santiago, Santiago Moreno, Agustin Albillos, Institut Català de la Salut, [Mateos-Muñoz B] Hospital Universitario Ramón y Cajal, CIBEREHD, IRYCIS, Universidad de Alcalá, Madrid, Spain. [Buti M, Marcos-Fosch C] Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBEREHD, Barcelona, Spain. [Fernández Vázquez I] Gastroenterology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain. [Hernández Conde M] Gastroenterology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain. [Bernal-Monterde V] Gastroenterology Department, Hospital Miguel Servet, Zaragoza, Spain. [Díaz-Fontenla F] Gastroenterology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Otros calificadores::/uso terapéutico [Otros calificadores], Physiology, Gastroenterology, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], virosis::infecciones por virus ADN::infecciones por Hepadnaviridae::hepatitis B::hepatitis B crónica [ENFERMEDADES], Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS], COVID-19 (Malaltia) - Tractament, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Medicaments antivírics - Ús terapèutic, Other subheadings::/therapeutic use [Other subheadings], Hepatitis B - Tractament, Virus Diseases::DNA Virus Infections::Hepadnaviridae Infections::Hepatitis B::Hepatitis B, Chronic [DISEASES]
Abstract: COVID-19; Hepatitis B; Tenofovir COVID-19; Hepatitis B; Tenofovir COVID-19; Hepatitis B; Tenofovir Background and Aims HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV). Methods Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19. Results Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p
Published: 2023

3. Dextran sulfate from Leuconostoc mesenteroides B512F exerts potent antiviral activity against SARS-CoV-2 in vitro and in vivo

Author: Andreu, Sabina, Kobbe Alonso, Cayetano von, Delgado Cañaveras, María del Pilar, Ripa Peralta, Inés, Buzón, Maria J., Genescà, Meritxell, Gironés Pujol, Nuria, Moral Salmoral, Javier de, Ramírez, Gustavo A., Zúñiga, Sonia, Enjuanes, Luis, López Guerrero, José Antonio, Bello-Morales Arroyo, Ángeles Raquel, UAM. Departamento de Biología Molecular, Institut Català de la Salut, [Andreu S, Ripa I] Department of Molecular Biology, Universidad Autónoma de Madrid, Madrid, Spain. Centro de Biología Molecular Severo Ochoa, Spanish National Research Council—Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain. [von Kobbe C, Delgado P] Centro de Biología Molecular Severo Ochoa, Spanish National Research Council—Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain. [Buzón MJ, Genescà M] Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Microbiology (medical), Otros calificadores::/uso terapéutico [Otros calificadores], Sodium, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Aspartate Aminotransferase, Alanine Aminotransferase, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Alkaline Phosphatase, Biología y Biomedicina / Biología, Microbiology, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS], COVID-19 (Malaltia) - Tractament, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS], Creatinine, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Potassium, Medicaments antivírics - Ús terapèutic, Urea, Other subheadings::/therapeutic use [Other subheadings]
Abstract: The emergent human coronavirus SARS-CoV-2 and its resistance to current drugs makes the need for new potent treatments for COVID-19 patients strongly necessary. Dextran sulfate (DS) polysaccharides have long demonstrated antiviral activity against different enveloped viruses in vitro. However, their poor bioavailability has led to their abandonment as antiviral candidates. Here, we report for the first time the broad-spectrum antiviral activity of a DS-based extrapolymeric substance produced by the lactic acid bacterium Leuconostoc mesenteroides B512F. Time of addition assays with SARS-CoV-2 pseudoviruses in in vitro models confirm the inhibitory activity of DSs in the early stages of viral infection (viral entry). In addition, this exopolysaccharide substance also reports broad-spectrum antiviral activity against several enveloped viruses such as SARS-CoV-2, HCoV229E, HSV-1, in in vitro models and in human lung tissue. The toxicity and antiviral capacity of DS from L. mesenteroides was tested in vivo in mouse models which are susceptible to SARS-CoV-2 infection. The described DS, administered by inhalation, a new route of administration for these types of polymers, shows strong inhibition of SARS-CoV-2 infection in vivo, significantly reducing animal mortality and morbidity at non-toxic doses. Therefore, we suggest that it may be considered as a potential candidate for antiviral therapy against SARS-CoV-2, Financial support for the study was provided by the REACT-EU 2021 grant from Comunidad de Madrid to the Project COVTRAVI19-CM, Plataformas y modelos preclínicos para el abordaje multidisciplinar en COVID-19 y en respuesta a futuras pandemias
Published: 2023

4. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial

Author: Fanlo, Patricia, del Carmelo Gracia Tello, Borja, Fonseca Aizpuru, Eva, Álvarez-Troncoso, Jorge, Gonzalez, Andrés, Prieto-González, Sergio, Bujan Rivas, Segundo, Institut Català de la Salut, [Fanlo P] Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario de Navarra, Pamplona, Spain. [Gracia-Tello BDC] Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Clínico Lozano Blesa, Zaragoza, Spain. [Fonseca Aizpuru E] Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital de Cabueñes, Gijón, Spain. [Álvarez-Troncoso J] Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital La Paz, Madrid, Spain. [Gonzalez A] Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Ramón y Cajal, Madrid, Spain. [Prieto-González S] Servicio de Enfermedades Autoinmunes Sistémicas, Hospital Clinic, Barcelona, Spain. [Buján-Rivas S] Unitat de Malalties Autoimmunes Sistèmiques, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: COVID-19 (Malaltia) - Tractament, Avaluació de resultats (Assistència sanitària), virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]
Abstract: Efficacy; Safety; COVID-19 Eficacia; Seguridad; COVID-19 Eficàcia; Seguretat; COVID-19 Importance COVID-19 pneumonia is often associated with hyperinflammation. The efficacy and safety of anakinra in treating patients with severe COVID-19 pneumonia and hyperinflammation are still unclear. Objective To assess the efficacy and safety of anakinra vs standard of care alone for patients with severe COVID-19 pneumonia and hyperinflammation. Design, Setting, and Participants The Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to COVID-19 (ANA-COVID-GEAS) was a multicenter, randomized, open-label, 2-group, phase 2/3 clinical trial conducted at 12 hospitals in Spain between May 8, 2020, and March 1, 2021, with a follow-up of 1 month. Participants were adult patients with severe COVID-19 pneumonia and hyperinflammation. Hyperinflammation was defined as interleukin-6 greater than 40 pg/mL, ferritin greater than 500 ng/mL, C-reactive protein greater than 3 mg/dL (rationale, ≥5 upper normal limit), and/or lactate dehydrogenase greater than 300 U/L. Severe pneumonia was considered if at least 1 of the following conditions was met: ambient air oxygen saturation 94% or less measured with a pulse oximeter, ratio of partial pressure O2 to fraction of inspired O2 of 300 or less, and/or a ratio of O2 saturation measured with pulse oximeter to fraction of inspired O2 of 350 or less. Data analysis was performed from April to October 2021. Interventions Usual standard of care plus anakinra (anakinra group) or usual standard of care alone (SoC group). Anakinra was given at a dose of 100 mg 4 times a day intravenously. Main Outcomes and Measures The primary outcome was the proportion of patients not requiring mechanical ventilation up to 15 days after treatment initiation, assessed on an intention-to-treat basis. Results A total of 179 patients (123 men [69.9%]; mean [SD] age, 60.5 [11.5] years) were randomly assigned to the anakinra group (92 patients) or to the SoC group (87 patients). The proportion of patients not requiring mechanical ventilation up to day 15 was not significantly different between groups (64 of 83 patients [77.1%] in the anakinra group vs 67 of 78 patients [85.9%] in the SoC group; risk ratio [RR], 0.90; 95% CI, 0.77-1.04; P = .16). Anakinra did not result in any difference in time to mechanical ventilation (hazard ratio, 1.72; 95% CI, 0.82-3.62; P = .14). There was no significant difference between groups in the proportion of patients not requiring invasive mechanical ventilation up to day 15 (RR, 0.99; 95% CI, 0.88-1.11; P > .99). Conclusions and Relevance In this randomized clinical trial, anakinra did not prevent the need for mechanical ventilation or reduce mortality risk compared with standard of care alone among hospitalized patients with severe COVID-19 pneumonia. Funding for this study was received from the Regional Government of Navarra, Spain (project 0011-3597-2020-000028 to Dr Fanlo), and drugs were provided by the company Swedish Orphan Biovitrum (Sobi).
Published: 2023

5. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies

Author: Salmanton-García, Jon, Marchesi, Francesco, Gomes da Silva, Maria, Farina, Francesca, Dávila-Valls, Julio, Bilgin, Yavuz M., Glenthøj, Andreas, Falces-Romero, Iker, Van Doesum, Jaap, Labrador, Jorge, Buquicchio, Caterina, El-Ashwah, Shaimaa, Petzer, Verena, Van Praet, Jens, Schönlein, Martin, Dargenio, Michelina, Méndez, Gustavo-Adolfo, Meers, Stef, Itri, Federico, Giordano, Antonio, Pinczés, László Imre, Espigado, Ildefonso, Stojanoski, Zlate, López-García, Alberto, Prezioso, Lucia, Jaksic, Ozren, Vena, Antonio, Fracchiolla, Nicola S., González-López, Tomás José, Colović, Natasa, Delia, Mario, Weinbergerová, Barbora, Marchetti, Monia, Marques de Almeida, Joyce, Finizio, Olimpia, Besson, Caroline, Biernat, Monika M., Valković, Toni, Lahmer, Tobias, Cuccaro, Annarosa, Ormazabal-Vélez, Irati, Batinić, Josip, Fernández, Noemí, De Jonge, Nick, Tascini, Carlo, Anastasopoulou, Amalia N., Duléry, Rémy, Del Principe, Maria Ilaria, Plantefeve, Gaëtan, Papa, Mario Virgilio, Nucci, Marcio, Jiménez, Moraima, Aujayeb, Avinash, Hernández-Rivas, José-Ángel, Merelli, Maria, Cattaneo, Chiara, Blennow, Ola, Nordlander, Anna, Cabirta, Alba, Varricchio, Gina, Sacchi, Maria Vittoria, Cordoba, Raul, Arellano, Elena, Gräfe, Stefanie K., Wolf, Dominik, Emarah, Ziad, Ammatuna, Emanuele, Hersby, Ditte Stampe, Martín-Pérez, Sonia, Nunes Rodrigues, Raquel, Rahimli, Laman, Pagano, Livio, Cornely, Oliver A., Registry, EPICOVIDEHA, Piukovics, Klára, De Ramón, Cristina, Danion, François, Yahya, Ayel, Guidetti, Anna, Garcia-Vidal, Carolina, Sili, Uluhan, Meletiadis, Joseph, De Kort, Elizabeth, Verga, Luisa, Serrano, Laura, Erben, Nurettin, Di Blasi, Roberta, Tragiannidis, Athanasios, Ribera-Santa Susana, José-María, Ommen, Hans-Beier, Busca, Alessandro, Coppola, Nicola, Bergantim, Rui, Dragonetti, Giulia, Criscuolo, Marianna, Fianchi, Luana, Bonanni, Matteo, Soto-Silva, Andrés, Mikulska, Malgorzata, Machado, Marina, Shan Kho, Chi, Hassan, Nazia, Gavriilaki, Eleni, Cordini, Gregorio, Chi, Louis Yi Ann, Eggerer, Matthias, Hoenigl, Martin, Prattes, Juergen, Jiménez-Lorenzo, María-Josefa, Zompi, Sofia, Zambrotta, Giovanni Paolo Maria, Çolak, Gökçe Melis, García-Poutón, Nicole, Aiello, Tommaso Francesco, Prin, Romane, Stamouli, Maria, Samarkos, Michail, Hematology, Institut Català de la Salut, [Salmanton-García J] University of Cologne, Faculty of Medicine, and University Hospital Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany. University of Cologne, Faculty of Medicine, and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany. German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany. [Marchesi F] Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Gomes da Silva M] Portuguese Institute of Oncology, Lisbon, Portugal. [Farina F] IRCCS Ospedale San Raffaele, Milan, Italy. [Dávila-Valls J] Hospital Nuestra Señora de Sonsoles, Ávila, Spain. [Bilgin YM] Department of Internal Medicine, ADRZ, Goes, the Netherlands. [Jiménez M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Sang - Càncer, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Other subheadings::Other subheadings::/drug therapy [Other subheadings], COVID-19 (Malaltia) - Tractament, Medicine and Health Sciences, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Medicaments antivírics - Ús terapèutic, Other subheadings::/therapeutic use [Other subheadings], 03.02. Klinikai orvostan, neoplasias::neoplasias por localización::neoplasias hematológicas [ENFERMEDADES], BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina, Otros calificadores::/uso terapéutico [Otros calificadores], SARS-CoV-2, COVID-19, Malignancy, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], General Medicine, Neoplasms::Neoplasms by Site::Hematologic Neoplasms [DISEASES], BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Infectology, Settore MED/15, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS], Settore MED/15 - MALATTIE DEL SANGUE, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS], BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Infektologija, Haematology, Nirmatrelvir
Abstract: COVID-19; Haematology; Nirmatrelvir COVID-19; Hematología; Nirmatrelvir COVID-19; Hematologia; Nirmatrelvir Background Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan–Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448–4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619–8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093–0.732) and obesity (aOR 0.105, 95%CI 0.014–0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration. Interpretation Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir. EPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).
Published: 2023

6. Recomanacions per a l’inici i el seguiment del tractament amb Paxlovid® per a pacients amb COVID-19 lleu-moderada amb risc alt de progressar a formes greus

Author: Departament de Salut
Subjects: COVID-19 (Malaltia) - Tractament, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Medicaments antivírics, Other subheadings::Other subheadings::/drug therapy [Other subheadings]
Abstract: Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paxlovid; Medicament antiviral Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paxlovid; Medicamento antiviral Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paxlovid; Antiviral medication Recomanacions per a l’inici i el seguiment del tractament amb Paxlovid® per a pacients amb COVID-19 lleu-moderada amb risc alt de progressar a formes greus.
Published: 2022

7. Convalescent plasma for SARS-CoV-2 infection: win or learn

Author: Enric Contreras-Barbeta, Jordi Rello, Anna Millan, Institut Català de la Salut, [Contreras-Barbeta E, Millan A] Blood and Tissue Bank of Catalonia, Barcelona, Spain. [Rello J] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Anesthesiology Clinical Research, CHRU Nîmes, Nîmes, France, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Pulmonary and Respiratory Medicine, Male, 2019-20 coronavirus outbreak, Convalescent plasma, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), viruses, Antibodies, Viral, Plasma, COVID-19 (Malaltia) - Tractament, Investigative Techniques::Immunologic Techniques::Immunization::Immunization, Passive [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos víricos [COMPUESTOS QUÍMICOS Y DROGAS], Medicine, Humans, Original Research Article, COVID-19 Serotherapy, Otros calificadores::/terapia [Otros calificadores], Aged, business.industry, SARS-CoV-2, Immunization, Passive, virus diseases, COVID-19, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Other subheadings::/therapy [Other subheadings], Middle Aged, Virology, Immunització, Editorial, Treatment Outcome, Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Viral [CHEMICALS AND DRUGS], técnicas de investigación::técnicas inmunológicas::inmunización::inmunización pasiva [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], business, Immunoglobulines, Standard therapy
Abstract: Background Several randomised clinical trials have studied convalescent plasma (CP) for COVID-19 using different protocols, with different SARS-CoV-2 neutralising-antibody-titres, at different time-points and severities of illness. Methods In the prospective multicentre DAWN-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising-antibody-titres (NT50) ≥1/320 was the product of choice for the study. Results Between May 2nd, 2020 and January 26th, 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median volume of 884 mL convalescent plasma (IQR 806–906 mL) was administered, and 80.68% of the units came from donors with neutralising-antibody-titres (NT50) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on Day 15 was not different between both groups (convalescent plasma: 83.74% (n=267) versus control: 84.05% (n=137) – Odds ratio 0.99 (0.59–1.66) – p-value=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms, and transfusion-related side effects were reported in 19/320 patients in the intervention group (5.94%). Conclusions Transfusion of 4 units of convalescent plasma with high neutralising-antibody-titres early in hospitalised COVID-19 patients did not result in a significant improvement of the clinical status, or a reduced mortality., Early transfusion of 4 units of high neutralising-antibody-titre convalescent plasma in hospitalised COVID-19 patients does not reduce mortality or the need for mechanical ventilation.
Published: 2022

8. Cytokine Hemoadsorption as Rescue Therapy for Critically Ill Patients With SARS-CoV-2 Pneumonia With Severe Respiratory Failure and Hypercytokinemia

Author: Juan Carlos Ruiz-Rodríguez, Luis Chiscano-Camón, Adolf Ruiz-Sanmartin, Clara Palmada, Erika Paola Plata-Menchaca, Clara Franco-Jarava, Marcos Pérez-Carrasco, Manuel Hernández-González, Ricard Ferrer, Institut Català de la Salut, [Ruiz-Rodríguez JC, Chiscano-Camón L, Ferrer R] Unitat de Cures Intensives, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Xoc, Disfunció Orgànica i Ressuscitació, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ruiz-Sanmartin A, Palmada C, Plata-Menchaca EP, Pérez-Carrasco M] Unitat de Cures Intensives, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Xoc, Disfunció Orgànica i Ressuscitació, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Jarava C, Hernández-González M] Servei d’Immunologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Medicine (General), medicine.medical_specialty, medicine.medical_treatment, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hypercytokinemia, SARS-CoV-2 pneumonia, R5-920, COVID-19 (Malaltia) - Tractament, Rescue therapy, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], medicine, Acute respiratory distress syndrome (ARDS), Intensive care medicine, Original Research, hemoadsorption, Hypercytokinemia, business.industry, Critically ill, acute respiratory distress syndrome (ARDS), Otros calificadores::Otros calificadores::/terapia [Otros calificadores], COVID-19, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], General Medicine, medicine.disease, Pneumònia vírica - Tractament, Pneumonia, Cytokine, Respiratory failure, Citocines, Other subheadings::Other subheadings::/therapy [Other subheadings], Medicine, business, Hemoadsorption
Abstract: Introduction: A dysregulated inflammatory response, known as “cytokine storm”, plays an important role in the pathophysiology of coronavirus 2019 disease (COVID-19). Identifying patients with a dysregulated inflammatory response and at high risk for severe respiratory failure, organ dysfunction, and death is clinically relevant, as they could benefit from the specific therapies, such as cytokine removal by hemoadsorption. This study aimed to evaluate cytokine hemoadsorption as rescue therapy in critically ill patients with SARS-CoV-2 pneumonia, severe respiratory failure refractory to prone positioning, and hypercytokinemia.Methods: In this single center, observational and retrospective study, critically ill patients with SARS-CoV-2 pneumonia, severe acute respiratory failure, and hypercytokinemia were analyzed. All the patients underwent cytokine hemoadsorption using CytoSorb® (Cytosorbents Europe, Berlin, Germany). The indication for treatment was acute respiratory failure, inadequate clinical response to the prone position, and hypercytokinemia.Results: Among a total of 343 patients who were admitted to the intensive care unit (ICU) due to SARS-CoV-2 infection between March 3, 2020 and June 22, 2020, six patients received rescue therapy with cytokine hemoadsorption. All the patients needed invasive mechanical ventilation and prone positioning. A significant difference was found in the pre- and post-treatment D-dimer (17,868 mcg/ml [4,196–45,287] vs. 4,488 mcg/ml [3,166–17,076], p = 0.046), C-reactive protein (12.9 mg/dl [10.6] vs. 3.5 mg/dl [2.8], p = 0.028), ferritin (1,539 mcg/L [764–27,414] vs. 1,197 ng/ml [524–3,857], p = 0.04) and interleukin-6 (17,367 pg/ml [4,539–22,532] vs. 2,403 pg/ml [917–3,724], p = 0.043) levels. No significant differences in the pre- and post-treatment interleukin-10 levels (22.3 pg/ml [19.2–191] vs. 5.6 pg/ml [5.2–36.6], p = 0.068) were observed. Improvements in oxygenation (prehemoadsorption PaO2/FIO2 ratio 103 [18.4] vs. posthemoadsorption PaO2/FIO2 ratio 222 [20.9], p = 0.029) and in the organ dysfunction (prehemoadsorption SOFA score 9 [4.75] vs. posthemoadsorption SOFA score 7.7 [5.4], p = 0.046) were observed. ICU and in-hospital mortality was 33.7%.Conclusions: In this case series, critically ill patients with COVID-19 with severe acute respiratory failure refractory to prone positioning and hypercytokinemia who received adjuvant treatment with cytokine hemoadsorption showed a significant reduction in IL-6 plasma levels and other inflammatory biomarkers. Improvements in oxygenation and SOFA score were also observed.
Published: 2022

9. Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

Author: Reyes, Luis Felipe, Murthy, Srinivas, Garcia-Gallo, Esteban, Merson, Laura, Ibáñez-Prada, Elsa, Rello, Jordi, Fuentes, Yuli, Martin-Loeches, Ignacio, Bozza, Fernando, Duque, Sara, Taccone, Fabio, Fowler, Robert, Kartsonaki, Christiana, Gonçalves, Bronner, Citarella, Barbara Wanjiru, Aryal, Diptesh, Burhan, Erlina, Cummings, Matthew, Delmas, Christelle, Diaz, Rodrigo, Figueiredo-Mello, Claudia, Hashmi, Madiha, Panda, Prasan Kumar, Jiménez, Miguel Pedrera, Rincon, Diego Fernando Bautista, Thomson, David, Nichol, Alistair, Marshall, John, Olliaro, Piero, Abbas, Ali, Abdukahil, Sheryl Ann, Abe, Ryuzo, Abel, Laurent, Absil, Lara, Acharya, Subhash, Acker, Andrew, Adrião, Diana, Al Ageel, Saleh, Ahmed, Shakeel, Ainscough, Kate, Aisa, Tharwat, Hssain, Ali Ait, Tamlihat, Younes Ait, Akimoto, Takako, Akmal, Ernita, Al Qasim, Eman, Alalqam, Razi, Al-Dabbous, Tala, Alegesan, Senthilkumar, Alegre, Cynthia, Alessi, Marta, Alex, Beatrice, Alexandre, Kévin, Al-Fares, Abdulrahman, Alfoudri, Huda, Ali, Imran, Shah, Naseem Ali, Alidjnou, Kazali Enagnon, Aliudin, Jeffrey, Alkhafajee, Qabas, Allavena, Clotilde, Allou, Nathalie, Altaf, Aneela, Alves, João, Alves, João Melo, Alves, Rita, Cabrita, Joana Alves, Amaral, Maria, Ampaw, Phoebe, Andini, Roberto, Andréjak, Claire, Angheben, Andrea, Angoulvant, François, Ansart, Séverine, Antonelli, Massimo, de Brito, Carlos Alexandre Antunes, Apriyana, Ardiyan, Arabi, Yaseen, Aragao, Irene, Araujo, Carolline, Arcadipane, Antonio, Archambault, Patrick, Arenz, Lukas, Arlet, Jean-Benoît, Arnold-Day, Christel, Arora, Lovkesh, Arora, Rakesh, Artaud-Macari, Elise, Asensio, Angel, Asif, Namra, Asim, Mohammad, Assie, Jean Baptiste, Atique, Anika, Attanyake, A., Auchabie, Johann, Aumaitre, Hugues, Auvet, Adrien, Azemar, Laurène, Azoulay, Cecile, Bach, Benjamin, Bachelet, Delphine, Badr, Claudine, Baig, Nadia, Baillie, J. Kenneth, Bak, Erica, Bakakos, Agamemnon, Bal, Andriy, Balan, Valeria, Bani-Sadr, Firouzé, Barbalho, Renata, Barclay, Wendy, Barnikel, Michaela, Barrasa, Helena, Barrelet, Audrey, Barrigoto, Cleide, Bartoli, Marie, Baruch, Joaquín, Basmaci, Romain, Battaglini, Denise, Bauer, Jules, Dow, Denisse Bazan, Beane, Abigail, Bedossa, Alexandra, Begum, Husna, Behilill, Sylvie, Beishuizen, Albertus, Beljantsev, Aleksandr, Bellemare, David, Beltrame, Anna, Beluze, Marine, Benech, Nicolas, Benkerrou, Dehbia, Bennett, Suzanne, Bento, Luís, Berdal, Jan-Erik, Bergeaud, Delphine, Bergin, Hazel, Sobrino, José Luis Bernal, Bertoli, Giulia, Bertolino, Lorenzo, Bessis, Simon, Bevilcaqua, Sybille, Bezulier, Karine, Bhatt, Amar, Bhavsar, Krishna, Bianco, Claudia, Singh, Moirangthem Bikram, Humaid, Felwa Bin, Bissuel, François, Bitker, Laurent, Bitton, Jonathan, Blanco-Schweizer, Pablo, Blier, Catherine, Bloos, Frank, Blot, Mathieu, Boccia, Filomena, Bodenes, Laetitia, Bogaert, Debby, Boivin, Anne-Hélène, Bolze, Pierre-Adrien, Bompart, François, Borges, Diogo, Borie, Raphaël, Bosse, Hans Martin, Botelho-Nevers, Elisabeth, Bouadma, Lila, Bouchaud, Olivier, Bouchez, Sabelline, Bouhmani, Dounia, Bouhour, Damien, Bouiller, Kévin, Bouillet, Laurence, Bouisse, Camile, Boureau, Anne-Sophie, Bourke, John, Bouscambert, Maude, Bousquet, Aurore, Bouziotis, Jason, Boxma, Bianca, Boyer-Besseyre, Marielle, Boylan, Maria, Braconnier, Axelle, Braga, Cynthia, Brandenburger, Timo, Monteiro, Filipa Brás, Brazzi, Luca, Breen, Dorothy, Breen, Patrick, Brickell, Kathy, Browne, Alex, Browne, Shaunagh, Brusse-Keizer, Marjolein, Buchtele, Nina, Buesaquillo, Christian, Bugaeva, Polina, Buisson, Marielle, Burrell, Aidan, Bustos, Ingrid, Butnaru, Denis, Cabie, André, Cabral, Susana, Caceres, Eder, Cadoz, Cyril, Garcês, Rui Caetano, Calligy, Kate, Calvache, Jose Andres, Camões, João, Campana, Valentine, Campbell, Paul, Canepa, Cecilia, Cantero, Mireia, Caraux-Paz, Pauline, Cárcel, Sheila, Cardellino, Chiara Simona, Cardoso, Filipa, Cardoso, Filipe, Cardoso, Nelson, Cardoso, Sofia, Carelli, Simone, Carlier, Nicolas, Carmoi, Thierry, Carney, Gayle, Carqueja, Inês, Carret, Marie-Christine, Carrier, François Martin, Carroll, Ida, Carson, Gail, Casanova, Maire-Laure, Cascão, Mariana, Casey, Siobhan, Casimiro, José, Cassandra, Bailey, Castañeda, Silvia, Castanheira, Nidyanara, Castor-Alexandre, Guylaine, Castrillón, Henry, Castro, Ivo, Catarino, Ana, Catherine, François-Xavier, Cattaneo, Paolo, Cavalin, Roberta, Cavalli, Giulio Giovanni, Cavayas, Alexandros, Ceccato, Adrian, Cervantes-Gonzalez, Minerva, Chair, Anissa, Chakveatze, Catherine, Chan, Adrienne, Chand, Meera, Auger, Christelle Chantalat, Chapplain, Jean-Marc, Chas, Julie, Chaudry, Mobin, Iñiguez, Jonathan Samuel Chávez, Chen, Anjellica, Chen, Yih-Sharng, Cheng, Matthew Pellan, Cheret, Antoine, Chiarabini, Thibault, Chica, Julian, Chirouze, Catherine, Chiumello, Davide, Cho, Sung-Min, Cholley, Bernard, Chopin, Marie-Charlotte, Cidade, Jose Pedro, Herreros, José Miguel Cisneros, Ciullo, Anna, Clarke, Emma, Clarke, Jennifer, Clohisey, Sara, Cobb, Perren, Codan, Cassidy, Cody, Caitriona, Coelho, Alexandra, Coles, Megan, Colin, Gwenhaël, Collins, Michael, Colombo, Sebastiano Maria, Combs, Pamela, Connor, Marie, Conrad, Anne, Contreras, Sofía, Conway, Elaine, Cooke, Graham, Copland, Mary, Cordel, Hugues, Corley, Amanda, Cornelis, Sabine, Cornet, Alexander Daniel, Corpuz, Arianne Joy, Cortegiani, Andrea, Corvaisier, Grégory, Costigan, Emma, Couffignal, Camille, Couffin-Cadiergues, Sandrine, Courtois, Roxane, Cousse, Stéphanie, Cregan, Rachel, Croonen, Sabine, Crowl, Gloria, Crump, Jonathan, Cruz, Claudina, Bermúdez, Juan Luis Cruz, Rojo, Jaime Cruz, Csete, Marc, Cullen, Ailbhe, Curley, Ger, Curlier, Elodie, Curran, Colleen, Custodio, Paula, da Silva Filipe, Ana, da Silveira, Charlene, Dabaliz, Al-Awwab, Dagens, Andrew, Dahly, Darren, Dalton, Heidi, Dalton, Jo, Daly, Seamus, Damas, Juliana, Daneman, Nick, Daniel, Corinne, Dankwa, Emmanuelle, Dantas, Jorge, D’aragon, Frédérick, de Loughry, Gillian, de Mendoza, Diego, de Montmollin, Etienne, de Oliveira França, Rafael Freitas, de Pinho Oliveira, Ana Isabel, de Rosa, Rosanna, de Silva, Thushan, de Vries, Peter, Deacon, Jillian, Dean, David, Debard, Alexa, Debray, Marie-Pierre, Decastro, Nathalie, Dechert, William, Deconninck, Lauren, Decours, Romain, Defous, Eve, Delacroix, Isabelle, Delaveuve, Eric, Delavigne, Karen, Dell’amore, Andrea, Delobel, Pierre, Delsing, Corine, Demonchy, Elisa, Denis, Emmanuelle, Deplanque, Dominique, Depuydt, Pieter, Descamps, Diane, Desvallées, Mathilde, Dewayanti, Santi, Dhanger, Pathik, Diallo, Alpha, Diamantis, Sylvain, Dias, André, Diaz, Juan Jose, Diaz, Priscila, Didier, Kévin, Diehl, Jean-Luc, Dieperink, Wim, Dimet, Jérôme, Dinot, Vincent, Diop, Fara, Diouf, Alphonsine, Dishon, Yael, Djossou, Félix, Docherty, Annemarie, Doherty, Helen, Dondorp, Arjen, Donnelly, Christl, Donnelly, Maria, Donohue, Chloe, Donohue, Sean, Donohue, Yoann, Doran, Peter, Dorival, Céline, D’ortenzio, Eric, Douglas, James Joshua, Dournon, Nathalie, Downer, Triona, Downey, Joanne, Downing, Mark, Drake, Tom, Driscoll, Aoife, Fonseca, Claudio Duarte, Dubee, Vincent, Dubos, François, Ducancelle, Alexandre, Dudman, Susanne, Dunand, Paul, Dunning, Jake, Duplaix, Mathilde, Durante-Mangoni, Emanuele, Durham, Lucian, Dussol, Bertrand, Duthoit, Juliette, Duval, Xavier, Dyrhol-Riise, Anne Margarita, Echeverria-Villalobos, Marco, Egan, Siobhan, Eira, Carla, Sanharawi, Mohammed El, Elapavaluru, Subbarao, Elharrar, Brigitte, Ellerbroek, Jacobien, Eloy, Philippine, Elshazly, Tarek, Enderle, Isabelle, Endo, Tomoyuki, Engelmann, Ilka, Enouf, Vincent, Epaulard, Olivier, Escher, Martina, Esperatti, Mariano, Esperou, Hélène, Santo, Catarina Espírito, Esposito-Farese, Marina, Estevão, João, Etienne, Manuel, Ettalhaoui, Nadia, Everding, Anna Greti, Evers, Mirjam, Fabre, Isabelle, Fabre, Marc, Faheem, Amna, Fahy, Arabella, Fairfield, Cameron, Fakar, Zul, Fareed, Komal, Faria, Pedro, Farooq, Ahmed, Fatoni, Arie Zainul, Faure, Karine, Favory, Raphaël, Fayed, Mohamed, Feely, Niamh, Feeney, Laura, Fernandes, Jorge, Fernandes, Marília Andreia, Fernandes, Susana, Ferrand, François-Xavier, Devouge, Eglantine Ferrand, Ferrão, Joana, Ferraz, Mário, Ferreira, Benigno, Ferreira, Bernardo, Ferreira, Isabel, Ferreira, Sílvia, Ferrer-Roca, Ricard, Ferriere, Nicolas, Ficko, Céline, Fiorda, Juan, Flament, Thomas, Flateau, Clara, Fletcher, Tom, Florio, Letizia Lucia, Flynn, Deirdre, Foley, Claire, Foley, Jean, Fomin, Victor, Fonseca, Tatiana, Fontela, Patricia, Forsyth, Simon, Foster, Denise, Foti, Giuseppe, Fourn, Erwan, Fraher, Marianne, Franch-Llasat, Diego, Fraser, Christophe, Fraser, John, Freire, Marcela Vieira, Ribeiro, Ana Freitas, French, Craig, Friedrich, Caren, Fry, Stéphanie, Fuentes, Nora, Fukuda, Masahiro, G, Argin, Gaborieau, Valérie, Gaci, Rostane, Gagliardi, Massimo, Gagnard, Jean-Charles, Gagneux-Brunon, Amandine, Gaião, Sérgio, Skeie, Linda Gail, Gallagher, Phil, Gamble, Carrol, Garan, Arthur, Garcia, Rebekha, Barrio, Noelia García, Garimella, Navya, Garot, Denis, Garrait, Valérie, Gauli, Basanta, Gault, Nathalie, Gavin, Aisling, Gavrylov, Anatoliy, Gaymard, Alexandre, Gebauer, Johannes, Geraud, Eva, Morlaes, Louis Gerbaud, Germano, Nuno, Ghosn, Jade, Giani, Marco, Gibson, Jess, Gigante, Tristan, Gilg, Morgane, Gilroy, Elaine, Giordano, Guillermo, Girvan, Michelle, Gissot, Valérie, Glikman, Daniel, Glybochko, Petr, Gnall, Eric, Goco, Geraldine, Goehringer, François, Goepel, Siri, Goffard, Jean-Christophe, Golob, Jonathan, Gómez-Junyent, Joan, Gominet, Marie, Gonzalez, Alicia, Gordon, Patricia, Gorenne, Isabelle, Goubert, Laure, Goujard, Cécile, Goulenok, Tiphaine, Grable, Margarite, Graf, Jeronimo, Grandin, Edward Wilson, Granier, Pascal, Grasselli, Giacomo, Green, Christopher, Greene, Courtney, Greenhalf, William, Greffe, Segolène, Grieco, Domenico Luca, Griffee, Matthew, Griffiths, Fiona, Groenendijk, Albert, Lordemann, Anja Grosse, Gruner, Heidi, Gu, Yusing, Guedj, Jérémie, Guego, Martin, Guellec, Dewi, Guerguerian, Anne-Marie, Guerreiro, Daniela, Guery, Romain, Guillaumot, Anne, Guilleminault, Laurent, de Castro, Maisa Guimarães, Guimard, Thomas, Haalboom, Marieke, Haber, Daniel, Habraken, Hannah, Hachemi, Ali, Hadri, Nadir, Haidri, Fakhir, Hakak, Sheeba, Hall, Adam, Hall, Matthew, Halpin, Sophie, Hameed, Jawad, Hamer, Ansley, Hamidfar, Rebecca, Hammond, Terese, Haniffa, Rashan, Hardwick, Hayley, Harrison, Ewen, Harrison, Janet, Harrison, Samuel Bernard Ekow, Hasan, Mohd Shahnaz, Hashmi, Junaid, Hayat, Muhammad, Hayes, Ailbhe, Hays, Leanne, Heerman, Jan, Heggelund, Lars, Hendry, Ross, Hennessy, Martina, Hentzien, Maxime, Hershey, Andrew, Hesstvedt, Liv, Hidayah, Astarini, Higgins, Dawn, Higgins, Eibhilin, Higgins, Rupert, Hinchion, Rita, Hinton, Samuel, Hitoto, Hikombo, Ho, Antonia, Hoctin, Alexandre, Hoffmann, Isabelle, Hoiting, Oscar, Holt, Rebecca, Holter, Jan Cato, Horby, Peter, Horcajada, Juan Pablo, Hoshino, Koji, Hoshino, Kota, Houas, Ikram, Hough, Catherine, Hsu, Jimmy Ming-Yang, Hulot, Jean-Sébastien, Huo, Stella, Hurd, Abby, Hussain, Iqbal, Ijaz, Samreen, Ikram, Arfan, Illes, Hajnal-Gabriela, Imbert, Patrick, Imran, Mohammad, Sikander, Rana Imran, Imtiaz, Aftab, Inácio, Hugo, Dominguez, Carmen Infante, Ippolito, Mariachiara, Isgett, Sarah, Isidoro, Tiago, Isnard, Margaux, Ivulich, Daniel, Jaafar, Danielle, Jaafoura, Salma, Jabot, Julien, Jackson, Clare, Jamieson, Nina, Jaquet, Pierre, Jaud-Fischer, Coline, Jaureguiberry, Stéphane, Jego, Florence, Jenum, Synne, García, Ruth, Joseph, Cédric, Joseph, Mark, Joshi, Swosti, Jourdain, Mercé, Jouvet, Philippe, Jung, Anna, Juzar, Dafsah, Kafif, Ouifiya, Kaguelidou, Florentia, Kali, Sabina, Kalomoiri, Smaragdi, Kandamby, Darshana Hewa, Kandel, Chris, Kanwal, Darakhshan, Kataria, Anant, Katz, Kevin, Kay, Christy, Keane, Hannah, Keating, Seán, Kelly, Andrea, Kelly, Aoife, Kelly, Claire, Kelly, Niamh, Kelly, Sadie, Kelly, Yvelynne, Kelsey, Maeve, Kennon, Kalynn, Kernan, Maeve, Kerroumi, Younes, Keshav, Sharma, Khalid, Imrana, Khalid, Osama, Khalil, Antoine, Khan, Coralie, Khan, Irfan, Khan, Quratul Ain, Khanal, Sushil, Khatak, Abid, Khawaja, Amin, Kho, Michelle, Khoo, Saye, Khoso, Nasir, Kida, Yuri, Kiiza, Peter, Granerud, Beathe Kiland, Kildal, Anders Benjamin, Kimmoun, Antoine, Kindgen-Milles, Detlef, Kitamura, Nobuya, Klenerman, Paul, Klont, Rob, Bekken, Gry Kloumann, Knight, Stephen, Kobbe, Robin, Kodippily, Chamira, Vasconcelos, Malte Kohns, Koirala, Sabin, Kosgei, Caroline, Kpangon, Arsène, Krawczyk, Karolina, Kruglova, Oksana, Kumar, Deepali, Kumar, Mukesh, Vijayaraghavan, Bharath Kumar Tirupakuzhi, Vecham, Pavan Kumar, Kuriakose, Dinesh, Kurtzman, Ethan, Kutsogiannis, Demetrios, Kutsyna, Galyna, Kyriakoulis, Konstantinos, Lachatre, Marie, Lacoste, Marie, Laffey, John, Lagrange, Marie, Laine, Fabrice, Lairez, Olivier, Lakhey, Sanjay, Lalueza, Antonio, Lambert, Marc, Lamontagne, François, Langelot-Richard, Marie, Langlois, Vincent, Lantang, Eka Yudha, Lanza, Marina, Laouénan, Cédric, Laribi, Samira, Lariviere, Delphine, Lasry, Stéphane, Latif, Naveed, Launay, Odile, Laureillard, Didier, Lavie-Badie, Yoan, Law, Andrew, Lawrence, Cassie, Lawrence, Teresa, Le, Minh, Le Bihan, Clément, Le Bris, Cyril, Le Falher, Georges, Le Fevre, Lucie, Le Hingrat, Quentin, Le Maréchal, Marion, Le Mestre, Soizic, Le Moal, Gwenaël, Le Moing, Vincent, Le Nagard, Hervé, Le Turnier, Paul, Leal, Ema, Santos, Marta Leal, Lee, James, Lee, Jennifer, Lee, Su Hwan, Lee, Todd, Leeming, Gary, Lefebvre, Bénédicte, Lefebvre, Laurent, Lefèvre, Benjamin, Legac, Sylvie, Lelievre, Jean-Daniel, Lellouche, François, Lemaignen, Adrien, Lemee, Véronique, Lemeur, Anthony, Lemmink, Gretchen, Lennon, Jenny, León, Rafael, Leone, Marc, Leone, Michela, Lescure, François-Xavier, Lesens, Olivier, Lesouhaitier, Mathieu, Lester-Grant, Amy, Levy, Bruno, Levy, Yves, Levy-Marchal, Claire, Lewandowska, Katarzyna, L’her, Erwan, Bassi, Gianluigi Li, Liaquat, Ali, Liegeon, Geoffrey, Lim, Wei Shen, Lima, Chantre, Lina, Bruno, Lind, Andreas, Lingas, Guillaume, Lion-Daolio, Sylvie, Liu, Keibun, Livrozet, Marine, Lizotte, Patricia, Loforte, Antonio, Lolong, Navy, Lopes, Diogo, Loschner, Anthony, Loubet, Paul, Loufti, Bouchra, Louis, Guillame, Lourenco, Silvia, Lovelace-Macon, Lara, Lowik, Marije, Lucet, Jean Christophe, Bermejo, Carlos Lumbreras, Luna, Carlos, Luong, Liem, Luque, Nestor, Luton, Dominique, Lwin, Nilar, Lyons, Ruth, Maasikas, Olavi, Mabiala, Oryane, Machado, Moïse, Machado, Sara, Macheda, Gabriel, Madiha, Hashmi, de la Calle, Guillermo Maestro, Mahieu, Rafael, Mahy, Sophie, Maia, Ana Raquel, Maier, Lars, Maillet, Mylène, Maitre, Thomas, Malfertheiner, Maximilian, Malik, Nadia, Mallon, Paddy, Maltez, Fernando, Malvy, Denis, Manda, Victoria, Mandelbrot, Laurent, Mankikian, Julie, Manning, Edmund, Manuel, Aldric, Sant, Ceila Maria, Malaque, Ana, Marino, Daniel, Marino, Flávio, Markowicz, Samuel, Marques, Ana, Marquis, Catherine, Marsh, Brian, Marsh, Laura, Marshal, Megan, Martelli, Celina Turchi, Martin, Emily, Martin-Blondel, Guillaume, Martinot, Martin, Martins, Ana, Martins, João, Martins, Nuno, Rego, Caroline Martins, Martucci, Gennaro, Martynenko, Olga, Marwali, Eva Miranda, Maslove, David, Mason, Sabina, Masood, Sobia, Nor, Basri Mat, Matan, Moshe, Mathew, Meghena, Mathieu, Daniel, Mattei, Mathieu, Matulevics, Romans, Maulin, Laurence, Maxwell, Michael, Maynar, Javier, Mazzoni, Thierry, Mc Evoy, Natalie, Mc Sweeney, Lisa, Mcarthur, Colin, Mccarthy, Aine, Mccarthy, Anne, Mccloskey, Colin, Mcconnochie, Rachael, Mcdermott, Sherry, Mcdonald, Sarah, Mcelroy, Aine, Mcelwee, Samuel, Mceneany, Victoria, Mcgeer, Allison, Mckay, Chris, Mckeown, Johnny, Mclean, Kenneth, Mcnally, Paul, Mcnicholas, Bairbre, Mcpartlan, Elaine, Meaney, Edel, Mear-Passard, Cécile, Mechlin, Maggie, Atif, Minahel, Meher, Maqsood, Mele, Ferruccio, Melo, Luis, Memon, Kashif, Mendes, Joao Joao, Menkiti, Ogechukwu, Menon, Kusum, Mentré, France, Mentzer, Alexander, Mercier, Emmanuelle, Mercier, Noémie, Merckx, Antoine, Mergeay-Fabre, Mayka, Mergler, Blake, Mesquita, António, Metwally, Osama, Meybeck, Agnès, Meyer, Dan, Meynert, Alison, Meysonnier, Vanina, Meziane, Amina, Mezidi, Mehdi, Michelanglei, Céline, Michelet, Isabelle, Mihnovit, Vladislav, Moin, Asma, Molina, David, Molinos, Elena, Molloy, Brenda, Mone, Mary, Monteiro, Agostinho, Montes, Claudia, Montrucchio, Giorgia, Moore, Sarah, Moore, Shona, Cely, Lina Morales, Moro, Lucia, Motherway, Catherine, Motos, Ana, Mouquet, Hugo, Perrot, Clara Mouton, Moyet, Julien, Mufti, Aisha Kalsoom, Mullaert, Jimmy, Müller, Fredrik, Müller, Karl Erik, Munblit, Daniel, Muneeb, Syed, Munir, Nadeem, Murphy, Aisling, Murphy, Lorna, Murris, Marlène, Musaab, Himed, Muvindi, Himasha, Myrodia, Dimitra Melia, Mohd-Hanafiah, Farah Nadia, Nagpal, Dave, Nagrebetsky, Alex, Narayanan, Nageswaran, Khan, Rashid Nasim, Nazerali-Maitland, Alasdair, Neant, Nadège, Nekliudov, Nikita, Neto, Raul, Neumann, Emily, Ng, Pauline Yeung, Nghi, Anthony, Nguyen, Duc, Choileain, Orna Ni, Leathlobhair, Niamh Ni, Nitayavardhana, Prompak, Nonas, Stephanie, Noret, Marion, Norman, Lisa, Notari, Alessandra, Noursadeghi, Mahdad, Nowinski, Adam, Nseir, Saad, Nunez, Jose, Nurnaningsih, Nurnaningsih, Nyamankolly, Elsa, Brien, Fionnuala, Callaghan, Annmarie, O’callaghan, Annmarie, Occhipinti, Giovanna, Oconnor, Derbrenn, O’donnell, Max, Ogston, Tawnya, Ogura, Takayuki, O’halloran, Sophie, O’hearn, Katie, Oliveira, João, Oliveira, Larissa, Ong, David, Oosthuyzen, Wilna, Opavsky, Anne, Openshaw, Peter, Orakzai, Saijad, Orozco-Chamorro, Claudia Milena, Ortoleva, Jamel, Osatnik, Javier, O’shea, Linda, O’sullivan, Miriam, Ouamara, Nadia, Ouissa, Rachida, Oziol, Eric, Pagadoy, Maïder, Pages, Justine, Palacios, Amanda, Palacios, Mario, Palmarini, Massimo, Panarello, Giovanna, Paneru, Hem, Panigada, Mauro, Pansu, Nathalie, Papadopoulos, Aurélie, Parke, Rachael, Parker, Melissa, Parra, Briseida, Pasha, Taha, Pasquier, Jérémie, Pastene, Bruno, Patauner, Fabian, Patrão, Luís, Patricio, Patricia, Patrier, Juliette, Patterson, Lisa, Pattnaik, Rajyabardhan, Paul, Christelle, Paul, Mical, Paulos, Jorge, Paxton, William, Payen, Jean-François, Peelman, Florent, Peiffer-Smadja, Nathan, Peigne, Vincent, Pejkovska, Mare, Pelosi, Paolo, Peltan, Ithan, Pereira, Rui, Perez, Daniel, Periel, Luis, Perpoint, Thomas, Pesenti, Antonio, Pestre, Vincent, Petrou, Lenka, Petrovic, Michele, Petrov-Sanchez, Ventzislava, Pettersen, Frank Olav, Peytavin, Gilles, Pharand, Scott, Picard, Walter, Picone, Olivier, Pierobon, Carola, Piersma, Djura, Pimentel, Carlos, Pinto, Raquel, Pires, Catarina, Pironneau, Isabelle, Piroth, Lionel, Pius, Riinu, Plantier, Laurent, Poissy, Julien, Pokeerbux, Ryadh, Poli, Sergio, Pollakis, Georgios, Ponscarme, Diane, Post, Andra-Maris, Postma, Douwe, Povoa, Pedro, Póvoas, Diana, Powis, Jeff, Prapa, Sofia, Preau, Sébastien, Prebensen, Christian, Preiser, Jean-Charles, Prinssen, Anton, Pritchard, Mark, Priyadarshani, Gamage Dona Dilanthi, Proença, Lucia, Pudota, Sravya, Puéchal, Oriane, Semedi, Bambang Pujo, Pulicken, Mathew, Purcell, Gregory, Quesada, Luisa, Quinones-Cardona, Vilmaris, González, Víctor Quirós, Quist-Paulsen, Else, Quraishi, Mohammed, Rabaud, Christian, Rabindrarajan, Ebenezer, Rafael, Aldo, Rafiq, Marie, Rahutullah, Arsalan, Rainieri, Fernando, Ramachandran, Pratheema, Ramakrishnan, Nagarajan, Ramalho, José, Rammaert, Blandine, Ramos, Grazielle Viana, Rana, Asim, Rangappa, Rajavardhan, Ranjan, Ritika, Rapp, Christophe, Rashan, Aasiyah, Rashan, Thalha, Rasheed, Ghulam, Rasmin, Menaldi, Rätsep, Indrek, Rau, Cornelius, Raza, Ali, Real, Andre, Rebaudet, Stanislas, Redl, Sarah, Reeve, Brenda, Rehman, Attaur, Reid, Liadain, Reikvam, Dag Henrik, Reis, Renato, Remppis, Jonathan, Remy, Martine, Ren, Hongru, Renk, Hanna, Resseguier, Anne-Sophie, Revest, Matthieu, Rewa, Oleksa, Reyes, Tiago, Ribeiro, Maria Ines, Richardson, David, Richardson, Denise, Richier, Laurent, Riera, Jordi, Rios, Ana, Rishu, Asgar, Rispal, Patrick, Risso, Karine, Rizer, Nicholas, Robba, Chiara, Roberto, André, Roberts, Stephanie, Robertson, David, Robineau, Olivier, Roche-Campo, Ferran, Rodari, Paola, Rodeia, Simão, Abreu, Julia Rodriguez, Roessler, Bernhard, Roger, Pierre-Marie, Rojek, Amanda, Romaru, Juliette, Roncon-Albuquerque, Roberto, Roriz, Mélanie, Rosa-Calatrava, Manuel, Rose, Michael, Rosenberger, Dorothea, Rossanese, Andrea, Rossetti, Matteo, Rossignol, Bénédicte, Rossignol, Patrick, Rousset, Stella, Roy, Carine, Roze, Benoît, Rusmawatiningtyas, Desy, Russell, Clark, Ryan, Maeve, Ryan, Maria, Ryckaert, Steffi, Holten, Aleksander Rygh, Saba, Isabela, Sadaf, Sairah, Sadat, Musharaf, Sahraei, Valla, Saidani, Nadia, Saint-Gilles, Maximilien, Sakiyalak, Pranya, Salahuddin, Nawal, Salazar, Leonardo, Saleem, Jodat, Sales, Gabriele, Sallaberry, Stéphane, Gandonniere, Charlotte Salmon, Salvator, Hélène, Sanchez, Olivier, Sanchez-Miralles, Angel, Sancho-Shimizu, Vanessa, Sandhu, Gyan, Sandhu, Zulfiqar, Sandrine, Pierre-François, Sandulescu, Oana, Santos, Marlene, Sarfo-Mensah, Shirley, Banheiro, Bruno Sarmento, Sarton, Benjamine, Satyapriya, Sree, Satyawati, Rumaisah, Saviciute, Egle, Schaffer, Justin, Schermer, Tjard, Scherpereel, Arnaud, Schneider, Marion, Schroll, Stephan, Schwameis, Michael, Scott, Janet, Scott-Brown, James, Sedillot, Nicholas, Seitz, Tamara, Selvanayagam, Jaganathan, Semaille, Caroline, Semple, Malcolm, Senneville, Eric, Sequeira, Filipa, Sequeira, Tânia, Neto, Ary Serpa, Balazote, Pablo Serrano, Shadowitz, Ellen, Shamsah, Mohammad, Sharjeel, Shaikh, Sharma, Pratima, Shaw, Catherine, Shaw, Victoria, Sheharyar, Ashraf, Shetty, Rajesh Mohan, Shi, Haixia, Shiekh, Mohiuddin, Shimizu, Keiki, Shrapnel, Sally, Shrestha, Shubha Kalyan, Shrestha, Pramesh Sundar, Shum, Hoi Ping, Mohammed, Nassima Si, Sibiude, Jeanne, Siddiqui, Atif, Sigfrid, Louise, Sillaots, Piret, Silva, Catarina, Silva, Maria Joao, Silva, Rogério, Sin, Wai Ching, Singh, Budha Charan, Singh, Punam, Sitompul, Pompini Agustina, Skogen, Vegard, Smith, Sue, Smood, Benjamin, Smyth, Coilin, Smyth, Michelle, Snacken, Morgane, So, Dominic, Solomon, Joshua, Solomon, Tom, Somers, Emily, Sommet, Agnès, Song, Myung Jin, Song, Rima, Song, Tae, Chia, Jack Song, Sotto, Albert, Soum, Edouard, Sousa, Ana Chora, Sousa, Marta, Uva, Maria Sousa, Sperry, Alexandra, Spinuzza, Elisabetta, Darshana, B., Sriskandan, Shiranee, Stabler, Sarah, Staudinger, Thomas, Stecher, Stephanie-Susanne, Stienstra, Ymkje, Stiksrud, Birgitte, Stolz, Eva, Stone, Amy, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Stuart, Ami, Stuart, David, Suen, Gabriel, Suen, Jacky, Sultana, Asfia, Summers, Charlotte, Supic, Dubravka, Surovcová, Magdalena, Svistunov, Andrey, Syrigos, Konstantinos, Sztajnbok, Jaques, Szuldrzynski, Konstanty, Tabrizi, Shirin, Tagherset, Lysa, Taleb, Sara, Talsma, Jelmer, Tampubolon, Maria Lawrensia, Tanaka, Hiroyuki, Taqdees, Huda, Taqi, Arshad, Tardivon, Coralie, Tattevin, Pierre, Taufik, M. Azhari, Tawfik, Hassan, Tedder, Richard, Teixeira, João, Tejada, Sofia, Tellier, Marie-Capucine, Téoulé, François, Terpstra, Pleun, Terrier, Olivier, Terzi, Nicolas, Tessier-Grenier, Hubert, Tey, Adrian, Thakur, Anand, Thibault, Vincent, Thiberville, Simon-Djamel, Thill, Benoît, Thompson, Shaun, Thomson, Emma, Thwaites, Ryan, Tierney, Paul, Tieroshyn, Vadim, Timashev, Peter, Timsit, Jean-François, Tissot, Noémie, Toki, Maria, Tonby, Kristian, Torre, Marta, Torres, Antoni, Torres, Margarida, Torres-Zevallos, Hernando, Towers, Michael, Trapani, Tony, Treoux, Théo, Tromeur, Cécile, Trontzas, Ioannis, Trouillon, Tiffany, Truong, Jeanne, Tual, Christelle, Tubiana, Sarah, Tuite, Helen, Turmel, Jean-Marie, Turtle, Lance, Twardowski, Pawel, Uchiyama, Makoto, Udayanga, P., Udy, Andrew, Ullrich, Roman, Uribe, Alberto, Usman, Asad, Uyeki, Timothy, Vajdovics, Cristinava, Val-Flores, Luís, Valran, Amélie, van de Velde, Stijn, van den Berge, Marcel, van der Palen, Job, van der Valk, Paul, van der Vekens, Nicky, van der Voort, Peter, van der Werf, Sylvie, van Gulik, Laura, van Hattem, Jarne, van Netten, Carolien, van Veen, Ilonka, Vanel, Noémie, Vanoverschelde, Henk, Varghese, Pooja, Vauchy, Charline, Veislinger, Aurélie, Vencken, Sebastian, Ventura, Sara, Verbon, Annelies, Vickers, James, Vidal, José Ernesto, Vieira, César, Vijayan, Deepak, Villanueva, Joy Ann, Villar, Judit, Villeneuve, Pierre-Marc, Villoldo, Andrea, Visseaux, Benoit, Visser, Hannah, Vitiello, Chiara, Vonkeman, Harald, Vuotto, Fanny, Shukeri, Wan Fadzlina Wan Muhd, Wang, Chih-Hsien, Webb, Steve, Wei, Jia, Weil, Katharina, Wesselius, Sanne, West, T. Eoin, Wham, Murray, Whelan, Bryan, White, Nicole, Wicky, Paul Henri, Wiedemann, Aurélie, Wijaya, Surya Otto, Wille, Keith, Willems, Suzette, Williams, Virginie, Wils, Evert-Jan, Yiu, Ng Wing, Wong, Calvin, Xynogalas, Ioannis, Yamazaki, Masaki, Yazdanpanah, Yazdan, Yelnik, Cécile, Yerkovich, Stephanie, Yokoyama, Toshiki, Yonis, Hodane, Yousif, Obada, Yuliarto, Saptadi, Zaaqoq, Akram, Zabbe, Marion, Zahran, Maram, Zambon, Maria, Zanella, Alberto, Zayyad, Hiba, Zoufaly, Alexander, Zucman, David, University of Oxford, University of La Sabana = Universitad de la Sabana, ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Institut Pasteur [Paris] (IP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), This work was supported by the UK Foreign, Commonwealth, and Development Office and Wellcome [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135], CIHR Coronavirus Rapid Research Funding Opportunity OV2170359, Grants from Rapid European COVID-19 Emergency Response research (RECOVER) [H2020 Project 101003589] and European Clinical Research Alliance on Infectious Diseases (ECRAID) [965313], The Imperial NIHR Biomedical Research Centre, The Cambridge NIHR Biomedical Research Centre, and Endorsed by the Irish Critical Care-Clinical Trials Group, co-ordinated in Ireland by the Irish Critical Care-Clinical Trials Network at University College Dublin and funded by the Health Research Board of Ireland [CTN-2014-12]. This work uses Data/Materials provided by patients and collected by the NHS as part of their care and support #DataSavesLives. The Data/materials used for this research were obtained from ISARIC4C. The COVID-19 Clinical Information Network (CO-CIN) data was collated by ISARIC4C Investigators. Data and Material provision were supported by grants from: the National Institute for Health Research (NIHR, award CO-CIN-01), the Medical Research Council (MRC, Grant MC_PC_19059), and the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at the University of Liverpool in partnership with Public Health England (PHE), (Award 200907), Wellcome Trust [Turtle, Lance-fellowship 205228/Z/16/Z], NIHR HPRU in Respiratory Infections at Imperial College London with PHE (Award 200927), Liverpool Experimental Cancer Medicine Centre (Grant C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (Award IS-BRC-1215-20013), and NIHR Clinical Research Network providing infrastructure support. This work was possible due to the dedication and hard work of the Norwegian SARS-CoV-2 study team and supported by grants from Research Council of Norway Grant No. 312780 and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner, The dedication and hard work of the Groote Schuur Hospital Covid ICU Team, and supported by the Groote Schuur nursing and University of Cape Town registrar bodies coordinated by the Division of Critical Care at the University of Cape Town, and supported by the COVID clinical management team, AIIMS, Rishikesh, India., European Project: 101003589, H2020-SC1-PHE-CORONAVIRUS-2020,RECOVER(2020), Reyes, Luis Felipe, Murthy, Sriniva, Garcia-Gallo, Esteban, Merson, Laura, Ibáñez-Prada, Elsa D., Rello, Jordi, Fuentes, Yuli V., Martin-Loeches, Ignacio, Bozza, Fernando, Duque, Sara, Taccone, Fabio S., Fowler, Robert A., Kartsonaki, Christiana, Gonçalves, Bronner P., Citarella, Barbara Wanjiru, Aryal, Diptesh, Burhan, Erlina, Cummings, Matthew J., Delmas, Christelle, Diaz, Rodrigo, Figueiredo-Mello, Claudia, Hashmi, Madiha, Panda, Prasan Kumar, Jiménez, Miguel Pedrera, Rincon, Diego Fernando Bautista, Thomson, David, Nichol, Alistair, Marshall, John C., Olliaro, Piero L., Abbas, Ali, Abdukahil, Sheryl Ann, Abe, Ryuzo, Abel, Laurent, Absil, Lara, Acharya, Subhash, Acker, Andrew, Adrião, Diana, Al Ageel, Saleh, Ahmed, Shakeel, Ainscough, Kate, Aisa, Tharwat, Hssain, Ali Ait, Tamlihat, Younes Ait, Akimoto, Takako, Akmal, Ernita, Al Qasim, Eman, Alalqam, Razi, Al-dabbous, Tala, Alegesan, Senthilkumar, Alegre, Cynthia, Alessi, Marta, Alex, Beatrice, Alexandre, Kévin, Al-Fares, Abdulrahman, Alfoudri, Huda, Ali, Imran, Shah, Naseem Ali, Alidjnou, Kazali Enagnon, Aliudin, Jeffrey, Alkhafajee, Qaba, Allavena, Clotilde, Allou, Nathalie, Altaf, Aneela, Alves, João, Alves, João Melo, Alves, Rita, Cabrita, Joana Alve, Amaral, Maria, Ampaw, Phoebe, Andini, Roberto, Andréjak, Claire, Angheben, Andrea, Angoulvant, Françoi, Ansart, Séverine, Antonelli, Massimo, de Brito, Carlos Alexandre Antune, Apriyana, Ardiyan, Arabi, Yaseen, Aragao, Irene, Araujo, Carolline, Arcadipane, Antonio, Archambault, Patrick, Arenz, Luka, Arlet, Jean-Benoît, Arnold-Day, Christel, Arora, Lovkesh, Arora, Rakesh, Artaud-Macari, Elise, Asensio, Angel, Asif, Namra, Asim, Mohammad, Assie, Jean Baptiste, Atique, Anika, Attanyake, A. M. Udara Lakshan, Auchabie, Johann, Aumaitre, Hugue, Auvet, Adrien, Azemar, Laurène, Azoulay, Cecile, Bach, Benjamin, Bachelet, Delphine, Badr, Claudine, Baig, Nadia, Baillie, J. Kenneth, Bak, Erica, Bakakos, Agamemnon, Bal, Andriy, Balan, Valeria, Bani-Sadr, Firouzé, Barbalho, Renata, Barclay, Wendy S., Barnikel, Michaela, Barrasa, Helena, Barrelet, Audrey, Barrigoto, Cleide, Bartoli, Marie, Baruch, Joaquín, Basmaci, Romain, Battaglini, Denise, Bauer, Jule, Dow, Denisse Bazan, Beane, Abigail, Bedossa, Alexandra, Begum, Husna, Behilill, Sylvie, Beishuizen, Albertu, Beljantsev, Aleksandr, Bellemare, David, Beltrame, Anna, Beluze, Marine, Benech, Nicola, Benkerrou, Dehbia, Bennett, Suzanne, Bento, Luí, Berdal, Jan-Erik, Bergeaud, Delphine, Bergin, Hazel, Sobrino, José Luis Bernal, Bertoli, Giulia, Bertolino, Lorenzo, Bessis, Simon, Bevilcaqua, Sybille, Bezulier, Karine, Bhatt, Amar, Bhavsar, Krishna, Bianco, Claudia, Singh, Moirangthem Bikram, Humaid, Felwa Bin, Bissuel, Françoi, Bitker, Laurent, Bitton, Jonathan, Blanco-Schweizer, Pablo, Blier, Catherine, Bloos, Frank, Blot, Mathieu, Boccia, Filomena, Bodenes, Laetitia, Bogaert, Debby, Boivin, Anne-Hélène, Bolze, Pierre-Adrien, Bompart, Françoi, Borges, Diogo, Borie, Raphaël, Bosse, Hans Martin, Botelho-Nevers, Elisabeth, Bouadma, Lila, Bouchaud, Olivier, Bouchez, Sabelline, Bouhmani, Dounia, Bouhour, Damien, Bouiller, Kévin, Bouillet, Laurence, Bouisse, Camile, Boureau, Anne-Sophie, Bourke, John, Bouscambert, Maude, Bousquet, Aurore, Bouziotis, Jason, Boxma, Bianca, Boyer-Besseyre, Marielle, Boylan, Maria, Braconnier, Axelle, Braga, Cynthia, Brandenburger, Timo, Monteiro, Filipa Brá, Brazzi, Luca, Breen, Dorothy, Breen, Patrick, Brickell, Kathy, Browne, Alex, Browne, Shaunagh, Brusse-Keizer, Marjolein, Buchtele, Nina, Buesaquillo, Christian, Bugaeva, Polina, Buisson, Marielle, Burrell, Aidan, Bustos, Ingrid G., Butnaru, Deni, Cabie, André, Cabral, Susana, Caceres, Eder, Cadoz, Cyril, Garcês, Rui Caetano, Calligy, Kate, Calvache, Jose Andre, Camões, João, Campana, Valentine, Campbell, Paul, Canepa, Cecilia, Cantero, Mireia, Caraux-Paz, Pauline, Cárcel, Sheila, Cardellino, Chiara Simona, Cardoso, Filipa, Cardoso, Filipe, Cardoso, Nelson, Cardoso, Sofia, Carelli, Simone, Carlier, Nicola, Carmoi, Thierry, Carney, Gayle, Carqueja, Inê, Carret, Marie-Christine, Carrier, François Martin, Carroll, Ida, Carson, Gail, Casanova, Maire-Laure, Cascão, Mariana, Casey, Siobhan, Casimiro, José, Cassandra, Bailey, Castañeda, Silvia, Castanheira, Nidyanara, Castor-Alexandre, Guylaine, Castrillón, Henry, Castro, Ivo, Catarino, Ana, Catherine, François-Xavier, Cattaneo, Paolo, Cavalin, Roberta, Cavalli, Giulio Giovanni, Cavayas, Alexandro, Ceccato, Adrian, Cervantes-Gonzalez, Minerva, Chair, Anissa, Chakveatze, Catherine, Chan, Adrienne, Chand, Meera, Auger, Christelle Chantalat, Chapplain, Jean-Marc, Chas, Julie, Chaudry, Mobin, Iñiguez, Jonathan Samuel Chávez, Chen, Anjellica, Chen, Yih-Sharng, Cheng, Matthew Pellan, Cheret, Antoine, Chiarabini, Thibault, Chica, Julian, Chirouze, Catherine, Chiumello, Davide, Cho, Sung-Min, Cholley, Bernard, Chopin, Marie-Charlotte, Cidade, Jose Pedro, Herreros, José Miguel Cisnero, Ciullo, Anna, Clarke, Emma, Clarke, Jennifer, Clohisey, Sara, Cobb, Perren J., Codan, Cassidy, Cody, Caitriona, Coelho, Alexandra, Coles, Megan, Colin, Gwenhaël, Collins, Michael, Colombo, Sebastiano Maria, Combs, Pamela, Connor, Marie, Conrad, Anne, Contreras, Sofía, Conway, Elaine, Cooke, Graham S., Copland, Mary, Cordel, Hugue, Corley, Amanda, Cornelis, Sabine, Cornet, Alexander Daniel, Corpuz, Arianne Joy, Cortegiani, Andrea, Corvaisier, Grégory, Costigan, Emma, Couffignal, Camille, Couffin-Cadiergues, Sandrine, Courtois, Roxane, Cousse, Stéphanie, Cregan, Rachel, Croonen, Sabine, Crowl, Gloria, Crump, Jonathan, Cruz, Claudina, Bermúdez, Juan Luis Cruz, Rojo, Jaime Cruz, Csete, Marc, Cullen, Ailbhe, Curley, Ger, Curlier, Elodie, Curran, Colleen, Custodio, Paula, da Silva Filipe, Ana, Da Silveira, Charlene, Dabaliz, Al-Awwab, Dagens, Andrew, Dahly, Darren, Dalton, Heidi, Dalton, Jo, Daly, Seamu, Damas, Juliana, Daneman, Nick, Daniel, Corinne, Dankwa, Emmanuelle A., Dantas, Jorge, D’Aragon, Frédérick, de Loughry, Gillian, de Mendoza, Diego, De Montmollin, Etienne, de Oliveira França, Rafael Freita, de Pinho Oliveira, Ana Isabel, De Rosa, Rosanna, de Silva, Thushan, de Vries, Peter, Deacon, Jillian, Dean, David, Debard, Alexa, Debray, Marie-Pierre, DeCastro, Nathalie, Dechert, William, Deconninck, Lauren, Decours, Romain, Defous, Eve, Delacroix, Isabelle, Delaveuve, Eric, Delavigne, Karen, Dell’Amore, Andrea, Delobel, Pierre, Delsing, Corine, Demonchy, Elisa, Denis, Emmanuelle, Deplanque, Dominique, Depuydt, Pieter, Descamps, Diane, Desvallées, Mathilde, Dewayanti, Santi, Dhanger, Pathik, Diallo, Alpha, Diamantis, Sylvain, Dias, André, Diaz, Juan Jose, Diaz, Priscila, Didier, Kévin, Diehl, Jean-Luc, Dieperink, Wim, Dimet, Jérôme, Dinot, Vincent, Diop, Fara, Diouf, Alphonsine, Dishon, Yael, Djossou, Félix, Docherty, Annemarie B., Doherty, Helen, Dondorp, Arjen M., Donnelly, Christl A., Donnelly, Maria, Donohue, Chloe, Donohue, Sean, Donohue, Yoann, Doran, Peter, Dorival, Céline, D’Ortenzio, Eric, Douglas, James Joshua, Dournon, Nathalie, Downer, Triona, Downey, Joanne, Downing, Mark, Drake, Tom, Driscoll, Aoife, Fonseca, Claudio Duarte, Dubee, Vincent, Dubos, Françoi, Ducancelle, Alexandre, Dudman, Susanne, Dunand, Paul, Dunning, Jake, Duplaix, Mathilde, Durante-Mangoni, Emanuele, Durham, Lucian, Dussol, Bertrand, Duthoit, Juliette, Duval, Xavier, Dyrhol-Riise, Anne Margarita, Echeverria-Villalobos, Marco, Egan, Siobhan, Eira, Carla, Sanharawi, Mohammed El, Elapavaluru, Subbarao, Elharrar, Brigitte, Ellerbroek, Jacobien, Eloy, Philippine, Elshazly, Tarek, Enderle, Isabelle, Endo, Tomoyuki, Engelmann, Ilka, Enouf, Vincent, Epaulard, Olivier, Escher, Martina, Esperatti, Mariano, Esperou, Hélène, Santo, Catarina Espírito, Esposito-Farese, Marina, Estevão, João, Etienne, Manuel, Ettalhaoui, Nadia, Everding, Anna Greti, Evers, Mirjam, Fabre, Isabelle, Fabre, Marc, Faheem, Amna, Fahy, Arabella, Fairfield, Cameron J., Fakar, Zul, Fareed, Komal, Faria, Pedro, Farooq, Ahmed, Fatoni, Arie Zainul, Faure, Karine, Favory, Raphaël, Fayed, Mohamed, Feely, Niamh, Feeney, Laura, Fernandes, Jorge, Fernandes, Marília Andreia, Fernandes, Susana, Ferrand, François-Xavier, Devouge, Eglantine Ferrand, Ferrão, Joana, Ferraz, Mário, Ferreira, Benigno, Ferreira, Bernardo, Ferreira, Isabel, Ferreira, Sílvia, Ferrer-Roca, Ricard, Ferriere, Nicola, Ficko, Céline, Fiorda, Juan, Flament, Thoma, Flateau, Clara, Fletcher, Tom, Florio, Letizia Lucia, Flynn, Deirdre, Foley, Claire, Foley, Jean, Fomin, Victor, Fonseca, Tatiana, Fontela, Patricia, Forsyth, Simon, Foster, Denise, Foti, Giuseppe, Fourn, Erwan, Fraher, Marianne, Franch-Llasat, Diego, Fraser, Christophe, Fraser, John F., Freire, Marcela Vieira, Ribeiro, Ana Freita, French, Craig, Friedrich, Caren, Fry, Stéphanie, Fuentes, Nora, Fukuda, Masahiro, G, Argin, Gaborieau, Valérie, Gaci, Rostane, Gagliardi, Massimo, Gagnard, Jean-Charle, Gagneux-Brunon, Amandine, Gaião, Sérgio, Skeie, Linda Gail, Gallagher, Phil, Gamble, Carrol, Garan, Arthur, Garcia, Rebekha, Barrio, Noelia García, Garimella, Navya, Garot, Deni, Garrait, Valérie, Gauli, Basanta, Gault, Nathalie, Gavin, Aisling, Gavrylov, Anatoliy, Gaymard, Alexandre, Gebauer, Johanne, Geraud, Eva, Morlaes, Louis Gerbaud, Germano, Nuno, Ghosn, Jade, Giani, Marco, Gibson, Je, Gigante, Tristan, Gilg, Morgane, Gilroy, Elaine, Giordano, Guillermo, Girvan, Michelle, Gissot, Valérie, Glikman, Daniel, Glybochko, Petr, Gnall, Eric, Goco, Geraldine, Goehringer, Françoi, Goepel, Siri, Goffard, Jean-Christophe, Golob, Jonathan, Gómez-Junyent, Joan, Gominet, Marie, Gonzalez, Alicia, Gordon, Patricia, Gorenne, Isabelle, Goubert, Laure, Goujard, Cécile, Goulenok, Tiphaine, Grable, Margarite, Graf, Jeronimo, Grandin, Edward Wilson, Granier, Pascal, Grasselli, Giacomo, Green, Christopher A., Greene, Courtney, Greenhalf, William, Greffe, Segolène, Grieco, Domenico Luca, Griffee, Matthew, Griffiths, Fiona, Groenendijk, Albert, Lordemann, Anja Grosse, Gruner, Heidi, Gu, Yusing, Guedj, Jérémie, Guego, Martin, Guellec, Dewi, Guerguerian, Anne-Marie, Guerreiro, Daniela, Guery, Romain, Guillaumot, Anne, Guilleminault, Laurent, de Castro, Maisa Guimarãe, Guimard, Thoma, Haalboom, Marieke, Haber, Daniel, Habraken, Hannah, Hachemi, Ali, Hadri, Nadir, Haidri, Fakhir, Hakak, Sheeba, Hall, Adam, Hall, Matthew, Halpin, Sophie, Hameed, Jawad, Hamer, Ansley, Hamidfar, Rebecca, Hammond, Terese, Haniffa, Rashan, Hardwick, Hayley, Harrison, Ewen M., Harrison, Janet, Harrison, Samuel Bernard Ekow, Hasan, Mohd Shahnaz, Hashmi, Junaid, Hayat, Muhammad, Hayes, Ailbhe, Hays, Leanne, Heerman, Jan, Heggelund, Lar, Hendry, Ro, Hennessy, Martina, Hentzien, Maxime, Hershey, Andrew, Hesstvedt, Liv, Hidayah, Astarini, Higgins, Dawn, Higgins, Eibhilin, Higgins, Rupert, Hinchion, Rita, Hinton, Samuel, Hitoto, Hikombo, Ho, Antonia, Hoctin, Alexandre, Hoffmann, Isabelle, Hoiting, Oscar, Holt, Rebecca, Holter, Jan Cato, Horby, Peter, Horcajada, Juan Pablo, Hoshino, Koji, Hoshino, Kota, Houas, Ikram, Hough, Catherine L., Hsu, Jimmy Ming-Yang, Hulot, Jean-Sébastien, Huo, Stella, Hurd, Abby, Hussain, Iqbal, Ijaz, Samreen, Ikram, Arfan, Illes, Hajnal-Gabriela, Imbert, Patrick, Imran, Mohammad, Sikander, Rana Imran, Imtiaz, Aftab, Inácio, Hugo, Dominguez, Carmen Infante, Ippolito, Mariachiara, Isgett, Sarah, Isidoro, Tiago, Isnard, Margaux, Ivulich, Daniel, Jaafar, Danielle, Jaafoura, Salma, Jabot, Julien, Jackson, Clare, Jamieson, Nina, Jaquet, Pierre, Jaud-Fischer, Coline, Jaureguiberry, Stéphane, Jego, Florence, Jenum, Synne, García, Ruth N. Jorge, Joseph, Cédric, Joseph, Mark, Joshi, Swosti, Jourdain, Mercé, Jouvet, Philippe, Jung, Anna, Juzar, Dafsah, Kafif, Ouifiya, Kaguelidou, Florentia, Kali, Sabina, Kalomoiri, Smaragdi, Kandamby, Darshana Hewa, Kandel, Chri, Kanwal, Darakhshan, Kataria, Anant, Katz, Kevin, Kay, Christy, Keane, Hannah, Keating, Seán, Kelly, Andrea, Kelly, Aoife, Kelly, Claire, Kelly, Niamh, Kelly, Sadie, Kelly, Yvelynne, Kelsey, Maeve, Kennon, Kalynn, Kernan, Maeve, Kerroumi, Youne, Keshav, Sharma, Khalid, Imrana, Khalid, Osama, Khalil, Antoine, Khan, Coralie, Khan, Irfan, Khan, Quratul Ain, Khanal, Sushil, Khatak, Abid, Khawaja, Amin, Kho, Michelle E., Khoo, Saye, Khoso, Nasir, Kida, Yuri, Kiiza, Peter, Granerud, Beathe Kiland, Kildal, Anders Benjamin, Kimmoun, Antoine, Kindgen-Milles, Detlef, Kitamura, Nobuya, Klenerman, Paul, Klont, Rob, Bekken, Gry Kloumann, Knight, Stephen R., Kobbe, Robin, Kodippily, Chamira, Vasconcelos, Malte Kohn, Koirala, Sabin, Kosgei, Caroline, Kpangon, Arsène, Krawczyk, Karolina, Kruglova, Oksana, Kumar, Deepali, Kumar, Mukesh, Vijayaraghavan, Bharath Kumar Tirupakuzhi, Vecham, Pavan Kumar, Kuriakose, Dinesh, Kurtzman, Ethan, Kutsogiannis, Demetrio, Kutsyna, Galyna, Kyriakoulis, Konstantino, Lachatre, Marie, Lacoste, Marie, Laffey, John G., Lagrange, Marie, Laine, Fabrice, Lairez, Olivier, Lakhey, Sanjay, Lalueza, Antonio, Lambert, Marc, Lamontagne, Françoi, Langelot-Richard, Marie, Langlois, Vincent, Lantang, Eka Yudha, Lanza, Marina, Laouénan, Cédric, Laribi, Samira, Lariviere, Delphine, Lasry, Stéphane, Latif, Naveed, Launay, Odile, Laureillard, Didier, Lavie-Badie, Yoan, Law, Andrew, Lawrence, Cassie, Lawrence, Teresa, Le, Minh, Le Bihan, Clément, Le Bris, Cyril, Le Falher, George, Le Fevre, Lucie, Le Hingrat, Quentin, Le Maréchal, Marion, Le Mestre, Soizic, Le Moal, Gwenaël, Le Moing, Vincent, Le Nagard, Hervé, Le Turnier, Paul, Leal, Ema, Santos, Marta Leal, Lee, Jame, Lee, Jennifer, Lee, Su Hwan, Lee, Todd C., Leeming, Gary, Lefebvre, Bénédicte, Lefebvre, Laurent, Lefèvre, Benjamin, LeGac, Sylvie, Lelievre, Jean-Daniel, Lellouche, Françoi, Lemaignen, Adrien, Lemee, Véronique, Lemeur, Anthony, Lemmink, Gretchen, Lennon, Jenny, León, Rafael, Leone, Marc, Leone, Michela, Lescure, François-Xavier, Lesens, Olivier, Lesouhaitier, Mathieu, Lester-Grant, Amy, Levy, Bruno, Levy, Yve, Levy-Marchal, Claire, Lewandowska, Katarzyna, L’Her, Erwan, Bassi, Gianluigi Li, Liaquat, Ali, Liegeon, Geoffrey, Lim, Wei Shen, Lima, Chantre, Lina, Bruno, Lind, Andrea, Lingas, Guillaume, Lion-Daolio, Sylvie, Liu, Keibun, Livrozet, Marine, Lizotte, Patricia, Loforte, Antonio, Lolong, Navy, Lopes, Diogo, Loschner, Anthony L., Loubet, Paul, Loufti, Bouchra, Louis, Guillame, Lourenco, Silvia, Lovelace-Macon, Lara, Lowik, Marije, Lucet, Jean Christophe, Bermejo, Carlos Lumbrera, Luna, Carlos M., Luong, Liem, Luque, Nestor, Luton, Dominique, Lwin, Nilar, Lyons, Ruth, Maasikas, Olavi, Mabiala, Oryane, Machado, Moïse, Machado, Sara, Macheda, Gabriel, Madiha, Hashmi, de la Calle, Guillermo Maestro, Mahieu, Rafael, Mahy, Sophie, Maia, Ana Raquel, Maier, Lars S., Maillet, Mylène, Maitre, Thoma, Malfertheiner, Maximilian, Malik, Nadia, Mallon, Paddy, Maltez, Fernando, Malvy, Deni, Manda, Victoria, Mandelbrot, Laurent, Mankikian, Julie, Manning, Edmund, Manuel, Aldric, Sant, Ceila Maria, Malaque, Ana, Marino, Daniel, Marino, Flávio, Markowicz, Samuel, Marques, Ana, Marquis, Catherine, Marsh, Brian, Marsh, Laura, Marshal, Megan, Martelli, Celina Turchi, Martin, Emily, Martin-Blondel, Guillaume, Martinot, Martin, Martins, Ana, Martins, João, Martins, Nuno, Rego, Caroline Martin, Martucci, Gennaro, Martynenko, Olga, Marwali, Eva Miranda, Maslove, David, Mason, Sabina, Masood, Sobia, Nor, Basri Mat, Matan, Moshe, Mathew, Meghena, Mathieu, Daniel, Mattei, Mathieu, Matulevics, Roman, Maulin, Laurence, Maxwell, Michael, Maynar, Javier, Mazzoni, Thierry, Mc Evoy, Natalie, Mc Sweeney, Lisa, McArthur, Colin, McCarthy, Aine, McCarthy, Anne, McCloskey, Colin, McConnochie, Rachael, McDermott, Sherry, McDonald, Sarah E., McElroy, Aine, McElwee, Samuel, McEneany, Victoria, McGeer, Allison, McKay, Chri, McKeown, Johnny, McLean, Kenneth A., McNally, Paul, McNicholas, Bairbre, McPartlan, Elaine, Meaney, Edel, Mear-Passard, Cécile, Mechlin, Maggie, Atif, Minahel, Meher, Maqsood, Mele, Ferruccio, Melo, Lui, Memon, Kashif, Mendes, Joao Joao, Menkiti, Ogechukwu, Menon, Kusum, Mentré, France, Mentzer, Alexander J., Mercier, Emmanuelle, Mercier, Noémie, Merckx, Antoine, Mergeay-Fabre, Mayka, Mergler, Blake, Mesquita, António, Metwally, Osama, Meybeck, Agnè, Meyer, Dan, Meynert, Alison M., Meysonnier, Vanina, Meziane, Amina, Mezidi, Mehdi, Michelanglei, Céline, Michelet, Isabelle, Mihnovit, Vladislav, Moin, Asma, Molina, David, Molinos, Elena, Molloy, Brenda, Mone, Mary, Monteiro, Agostinho, Montes, Claudia, Montrucchio, Giorgia, Moore, Sarah, Moore, Shona C., Cely, Lina Morale, Moro, Lucia, Motherway, Catherine, Motos, Ana, Mouquet, Hugo, Perrot, Clara Mouton, Moyet, Julien, Mufti, Aisha Kalsoom, Mullaert, Jimmy, Müller, Fredrik, Müller, Karl Erik, Munblit, Daniel, Muneeb, Syed, Munir, Nadeem, Murphy, Aisling, Murphy, Lorna, Murris, Marlène, Musaab, Himed, Muvindi, Himasha, Myrodia, Dimitra Melia, Mohd-Hanafiah, Farah Nadia, Nagpal, Dave, Nagrebetsky, Alex, Narayanan, Nageswaran, Khan, Rashid Nasim, Nazerali-Maitland, Alasdair, Neant, Nadège, Nekliudov, Nikita, Neto, Raul, Neumann, Emily, Ng, Pauline Yeung, Nghi, Anthony, Nguyen, Duc, Choileain, Orna Ni, Leathlobhair, Niamh Ni, Nitayavardhana, Prompak, Nonas, Stephanie, Noret, Marion, Norman, Lisa, Notari, Alessandra, Noursadeghi, Mahdad, Nowinski, Adam, Nseir, Saad, Nunez, Jose I., Nurnaningsih, Nurnaningsih, Nyamankolly, Elsa, Brien, Fionnuala O., Callaghan, Annmarie O., O’Callaghan, Annmarie, Occhipinti, Giovanna, OConnor, Derbrenn, O’Donnell, Max, Ogston, Tawnya, Ogura, Takayuki, O’Halloran, Sophie, O’Hearn, Katie, Oliveira, João, Oliveira, Larissa, Ong, David S. Y., Oosthuyzen, Wilna, Opavsky, Anne, Openshaw, Peter, Orakzai, Saijad, Orozco-Chamorro, Claudia Milena, Ortoleva, Jamel, Osatnik, Javier, O’Shea, Linda, O’Sullivan, Miriam, Ouamara, Nadia, Ouissa, Rachida, Oziol, Eric, Pagadoy, Maïder, Pages, Justine, Palacios, Amanda, Palacios, Mario, Palmarini, Massimo, Panarello, Giovanna, Paneru, Hem, Panigada, Mauro, Pansu, Nathalie, Papadopoulos, Aurélie, Parke, Rachael, Parker, Melissa, Parra, Briseida, Pasha, Taha, Pasquier, Jérémie, Pastene, Bruno, Patauner, Fabian, Patrão, Luí, Patricio, Patricia, Patrier, Juliette, Patterson, Lisa, Pattnaik, Rajyabardhan, Paul, Christelle, Paul, Mical, Paulos, Jorge, Paxton, William A., Payen, Jean-Françoi, Peelman, Florent, Peiffer-Smadja, Nathan, Peigne, Vincent, Pejkovska, Mare, Pelosi, Paolo, Peltan, Ithan D., Pereira, Rui, Perez, Daniel, Periel, Lui, Perpoint, Thoma, Pesenti, Antonio, Pestre, Vincent, Petrou, Lenka, Petrovic, Michele, Petrov-Sanchez, Ventzislava, Pettersen, Frank Olav, Peytavin, Gille, Pharand, Scott, Picard, Walter, Picone, Olivier, Pierobon, Carola, Piersma, Djura, Pimentel, Carlo, Pinto, Raquel, Pires, Catarina, Pironneau, Isabelle, Piroth, Lionel, Pius, Riinu, Plantier, Laurent, Poissy, Julien, Pokeerbux, Ryadh, Poli, Sergio, Pollakis, Georgio, Ponscarme, Diane, Post, Andra-Mari, Postma, Douwe F., Povoa, Pedro, Póvoas, Diana, Powis, Jeff, Prapa, Sofia, Preau, Sébastien, Prebensen, Christian, Preiser, Jean-Charle, Prinssen, Anton, Pritchard, Mark G., Priyadarshani, Gamage Dona Dilanthi, Proença, Lucia, Pudota, Sravya, Puéchal, Oriane, Semedi, Bambang Pujo, Pulicken, Mathew, Purcell, Gregory, Quesada, Luisa, Quinones-Cardona, Vilmari, González, Víctor Quiró, Quist-Paulsen, Else, Quraishi, Mohammed, Rabaud, Christian, Rabindrarajan, Ebenezer, Rafael, Aldo, Rafiq, Marie, Rahutullah, Arsalan, Rainieri, Fernando, Ramachandran, Pratheema, Ramakrishnan, Nagarajan, Ramalho, José, Rammaert, Blandine, Ramos, Grazielle Viana, Rana, Asim, Rangappa, Rajavardhan, Ranjan, Ritika, Rapp, Christophe, Rashan, Aasiyah, Rashan, Thalha, Rasheed, Ghulam, Rasmin, Menaldi, Rätsep, Indrek, Rau, Corneliu, Raza, Ali, Real, Andre, Rebaudet, Stanisla, Redl, Sarah, Reeve, Brenda, Rehman, Attaur, Reid, Liadain, Reikvam, Dag Henrik, Reis, Renato, Remppis, Jonathan, Remy, Martine, Ren, Hongru, Renk, Hanna, Resseguier, Anne-Sophie, Revest, Matthieu, Rewa, Oleksa, Reyes, Tiago, Ribeiro, Maria Ine, Richardson, David, Richardson, Denise, Richier, Laurent, Riera, Jordi, Rios, Ana L., Rishu, Asgar, Rispal, Patrick, Risso, Karine, Rizer, Nichola, Robba, Chiara, Roberto, André, Roberts, Stephanie, Robertson, David L., Robineau, Olivier, Roche-Campo, Ferran, Rodari, Paola, Rodeia, Simão, Abreu, Julia Rodriguez, Roessler, Bernhard, Roger, Pierre-Marie, Rojek, Amanda, Romaru, Juliette, Roncon-Albuquerque, Roberto, Roriz, Mélanie, Rosa-Calatrava, Manuel, Rose, Michael, Rosenberger, Dorothea, Rossanese, Andrea, Rossetti, Matteo, Rossignol, Bénédicte, Rossignol, Patrick, Rousset, Stella, Roy, Carine, Roze, Benoît, Rusmawatiningtyas, Desy, Russell, Clark D., Ryan, Maeve, Ryan, Maria, Ryckaert, Steffi, Holten, Aleksander Rygh, Saba, Isabela, Sadaf, Sairah, Sadat, Musharaf, Sahraei, Valla, Saidani, Nadia, Saint-Gilles, Maximilien, Sakiyalak, Pranya, Salahuddin, Nawal, Salazar, Leonardo, Saleem, Jodat, Sales, Gabriele, Sallaberry, Stéphane, Gandonniere, Charlotte Salmon, Salvator, Hélène, Sanchez, Olivier, Sanchez-Miralles, Angel, Sancho-Shimizu, Vanessa, Sandhu, Gyan, Sandhu, Zulfiqar, Sandrine, Pierre-Françoi, Sandulescu, Oana, Santos, Marlene, Sarfo-Mensah, Shirley, Banheiro, Bruno Sarmento, Sarton, Benjamine, Satyapriya, Sree, Satyawati, Rumaisah, Saviciute, Egle, Schaffer, Justin, Schermer, Tjard, Scherpereel, Arnaud, Schneider, Marion, Schroll, Stephan, Schwameis, Michael, Scott, Janet T., Scott-Brown, Jame, Sedillot, Nichola, Seitz, Tamara, Selvanayagam, Jaganathan, Semaille, Caroline, Semple, Malcolm G., Senneville, Eric, Sequeira, Filipa, Sequeira, Tânia, Neto, Ary Serpa, Balazote, Pablo Serrano, Shadowitz, Ellen, Shamsah, Mohammad, Sharjeel, Shaikh, Sharma, Pratima, Shaw, Catherine A., Shaw, Victoria, Sheharyar, Ashraf, Shetty, Rajesh Mohan, Shi, Haixia, Shiekh, Mohiuddin, Shimizu, Keiki, Shrapnel, Sally, Shrestha, Shubha Kalyan, Shrestha, Pramesh Sundar, Shum, Hoi Ping, Mohammed, Nassima Si, Sibiude, Jeanne, Siddiqui, Atif, Sigfrid, Louise, Sillaots, Piret, Silva, Catarina, Silva, Maria Joao, Silva, Rogério, Sin, Wai Ching, Singh, Budha Charan, Singh, Punam, Sitompul, Pompini Agustina, Skogen, Vegard, Smith, Sue, Smood, Benjamin, Smyth, Coilin, Smyth, Michelle, Snacken, Morgane, So, Dominic, Solomon, Joshua, Solomon, Tom, Somers, Emily, Sommet, Agnè, Song, Myung Jin, Song, Rima, Song, Tae, Chia, Jack Song, Sotto, Albert, Soum, Edouard, Sousa, Ana Chora, Sousa, Marta, Uva, Maria Sousa, Sperry, Alexandra, Spinuzza, Elisabetta, Darshana, B. P. Sanka Ruwan Sri, Sriskandan, Shiranee, Stabler, Sarah, Staudinger, Thoma, Stecher, Stephanie-Susanne, Stienstra, Ymkje, Stiksrud, Birgitte, Stolz, Eva, Stone, Amy, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Stuart, Ami, Stuart, David, Suen, Gabriel, Suen, Jacky Y., Sultana, Asfia, Summers, Charlotte, Supic, Dubravka, Surovcová, Magdalena, Svistunov, Andrey, Syrigos, Konstantino, Sztajnbok, Jaque, Szuldrzynski, Konstanty, Tabrizi, Shirin, Tagherset, Lysa, Taleb, Sara, Talsma, Jelmer, Tampubolon, Maria Lawrensia, Tanaka, Hiroyuki, Taqdees, Huda, Taqi, Arshad, Tardivon, Coralie, Tattevin, Pierre, Taufik, M. Azhari, Tawfik, Hassan, Tedder, Richard S., Teixeira, João, Tejada, Sofia, Tellier, Marie-Capucine, Téoulé, Françoi, Terpstra, Pleun, Terrier, Olivier, Terzi, Nicola, Tessier-Grenier, Hubert, Tey, Adrian, Thakur, Anand, Thibault, Vincent, Thiberville, Simon-Djamel, Thill, Benoît, Thompson, Shaun, Thomson, Emma C., Thwaites, Ryan S., Tierney, Paul, Tieroshyn, Vadim, Timashev, Peter S., Timsit, Jean-Françoi, Tissot, Noémie, Toki, Maria, Tonby, Kristian, Torre, Marta, Torres, Antoni, Torres, Margarida, Torres-Zevallos, Hernando, Towers, Michael, Trapani, Tony, Treoux, Théo, Tromeur, Cécile, Trontzas, Ioanni, Trouillon, Tiffany, Truong, Jeanne, Tual, Christelle, Tubiana, Sarah, Tuite, Helen, Turmel, Jean-Marie, Turtle, Lance C. W., Twardowski, Pawel, Uchiyama, Makoto, Udayanga, P. G. Ishara, Udy, Andrew, Ullrich, Roman, Uribe, Alberto, Usman, Asad, Uyeki, Timothy M., Vajdovics, Cristinava, Val-Flores, Luí, Valran, Amélie, Van de Velde, Stijn, van den Berge, Marcel, van der Palen, Job, van der Valk, Paul, Van Der Vekens, Nicky, Van der Voort, Peter, Van Der Werf, Sylvie, van Gulik, Laura, Van Hattem, Jarne, van Netten, Carolien, van Veen, Ilonka, Vanel, Noémie, Vanoverschelde, Henk, Varghese, Pooja, Vauchy, Charline, Veislinger, Aurélie, Vencken, Sebastian, Ventura, Sara, Verbon, Annelie, Vickers, Jame, Vidal, José Ernesto, Vieira, César, Vijayan, Deepak, Villanueva, Joy Ann, Villar, Judit, Villeneuve, Pierre-Marc, Villoldo, Andrea, Visseaux, Benoit, Visser, Hannah, Vitiello, Chiara, Vonkeman, Harald, Vuotto, Fanny, Shukeri, Wan Fadzlina Wan Muhd, Wang, Chih-Hsien, Webb, Steve, Wei, Jia, Weil, Katharina, Wesselius, Sanne, West, T. Eoin, Wham, Murray, Whelan, Bryan, White, Nicole, Wicky, Paul Henri, Wiedemann, Aurélie, Wijaya, Surya Otto, Wille, Keith, Willems, Suzette, Williams, Virginie, Wils, Evert-Jan, Yiu, Ng Wing, Wong, Calvin, Xynogalas, Ioanni, Yamazaki, Masaki, Yazdanpanah, Yazdan, Yelnik, Cécile, Yerkovich, Stephanie, Yokoyama, Toshiki, Yonis, Hodane, Yousif, Obada, Yuliarto, Saptadi, Zaaqoq, Akram, Zabbe, Marion, Zahran, Maram, Zambon, Maria, Zanella, Alberto, Zayyad, Hiba, Zoufaly, Alexander, Zucman, David, Group, ISARIC Characterization, Intensive Care Medicine, AII - Amsterdam institute for Infection and Immunity, Medical Microbiology and Infection Prevention, AII - Inflammatory diseases, Ibáñez-Prada, Elsa D, Fuentes, Yuli V, Taccone, Fabio S, Fowler, Robert A, Gonçalves, Bronner P, Cummings, Matthew J, Marshall, John C, Olliaro, Piero L, Institut Català de la Salut, [Reyes LF] Pandemic Sciences Institute, University of Oxford, Oxford, UK. Infectious Diseases Department, Universidad de La Sabana, Chía, Colombia. Critical Care Department, Clínica Universidad de La Sabana, Chía, Colombia. [Murthy S] Department of Pediatrics, University of British Columbia, Vancouver, Canada. [Garcia-Gallo E] Infectious Diseases Department, Universidad de La Sabana, Chía, Colombia. [Merson L] Pandemic Sciences Institute, University of Oxford, Oxford, UK. [Ibáñez-Prada ED] Infectious Diseases Department, Universidad de La Sabana, Chía, Colombia. Critical Care Department, Clínica Universidad de La Sabana, Chía, Colombia. [Rello J] Grup de Recerca Clínica/Innovació en la Pneumònia i Sèpsia (CRIPS), Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica En Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: enfermedades respiratorias::trastornos respiratorios::insuficiencia respiratoria [ENFERMEDADES], COVID-19, Critical care, High flow nasal cannula, Invasive mechanical ventilation, Respiració artificial, Critical Care and Intensive Care Medicine, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, COVID-19 (Malaltia) - Tractament, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Humans, Prospective Studies, SARS-CoV-2, Tachypnea, Respiratory Insufficiency, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Otros calificadores::/terapia [Otros calificadores], Insuficiència respiratòria - Tractament, Therapeutics::Therapeutics::Respiratory Therapy::Respiration, Artificial::Noninvasive Ventilation [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Other subheadings::/therapy [Other subheadings], terapéutica::terapéutica::terapia respiratoria::respiración artificial::ventilación no invasiva [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Respiratory Tract Diseases::Respiration Disorders::Respiratory Insufficiency [DISEASES], Prospective Studie, Human
Abstract: Invasive mechanical ventilation; COVID-19; Critical care Ventilación mecánica invasiva; COVID-19; Cuidado crítico Ventilació mecànica invasiva; COVID-19; Atenció crítica Background Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support. Results A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83–7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97–2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14–1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25–1.30]). Conclusions In the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. This work was supported by the UK Foreign, Commonwealth, and Development Office and Wellcome [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135]; CIHR Coronavirus Rapid Research Funding Opportunity OV2170359; Grants from Rapid European COVID-19 Emergency Response research (RECOVER) [H2020 Project 101003589] and European Clinical Research Alliance on Infectious Diseases (ECRAID) [965313]; The Imperial NIHR Biomedical Research Centre; The Cambridge NIHR Biomedical Research Centre; and Endorsed by the Irish Critical Care-Clinical Trials Group, co-ordinated in Ireland by the Irish Critical Care-Clinical Trials Network at University College Dublin and funded by the Health Research Board of Ireland [CTN-2014-12]. This work uses Data/Materials provided by patients and collected by the NHS as part of their care and support #DataSavesLives. The Data/materials used for this research were obtained from ISARIC4C. The COVID-19 Clinical Information Network (CO-CIN) data was collated by ISARIC4C Investigators. Data and Material provision were supported by grants from: the National Institute for Health Research (NIHR; award CO-CIN-01), the Medical Research Council (MRC; Grant MC_PC_19059), and the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at the University of Liverpool in partnership with Public Health England (PHE), (Award 200907), Wellcome Trust [Turtle, Lance-fellowship 205228/Z/16/Z], NIHR HPRU in Respiratory Infections at Imperial College London with PHE (Award 200927), Liverpool Experimental Cancer Medicine Centre (Grant C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (Award IS-BRC-1215-20013), and NIHR Clinical Research Network providing infrastructure support. This work was possible due to the dedication and hard work of the Norwegian SARS-CoV-2 study team and supported by grants from Research Council of Norway Grant No. 312780 and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner; The dedication and hard work of the Groote Schuur Hospital Covid ICU Team, and supported by the Groote Schuur nursing and University of Cape Town registrar bodies coordinated by the Division of Critical Care at the University of Cape Town; and supported by the COVID clinical management team, AIIMS, Rishikesh, India.
Published: 2022
Full Text: View/download PDF

10. Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication

Author: Jerneja Kladnik, Ana Dolinar, Jakob Kljun, David Perea, Judith Grau-Expósito, Meritxell Genescà, Marko Novinec, Maria J. Buzon, Iztok Turel, Institut Català de la Salut, [Kladnik J, Dolinar A, Kljun J, Novinec M, Turel I] Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, Slovenia. [Perea D, Grau-Expósito J, Genescà M, Buzon MJ] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Pharmacology, compuestos orgánicos::compuestos organometálicos [COMPUESTOS QUÍMICOS Y DROGAS], SARS-CoV-2, pirition, zinc, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], General Medicine, Other subheadings::Other subheadings::/drug therapy [Other subheadings], udc:546.47:61:577, cink, inhibition, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS], inhibicija, COVID-19 (Malaltia) - Tractament, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS], antiviral agents, Drug Discovery, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Medicaments antivírics - Ús terapèutic, protivirusna zdravila, Compostos organometàl·lics, Organic Chemicals::Organometallic Compounds [CHEMICALS AND DRUGS], pyrithione
Abstract: As SARS-CoV-2 triggered a global health crisis, there is an urgent need to provide patients with safe, effective, accessible, and preferably oral therapeutics for COVID-19 that complement mRNA vaccines. Zinc compounds are widely known for their antiviral properties. Therefore, we have prepared a library of zinc complexes with pyrithione (1-hydroxy-2(1H)-pyridinethione) and its analogues, all of which showed promising in vitro inhibition of cathepsin L, an enzyme involved in SARS-CoV-2 entry, and PLPro, an enzyme involved in SARS-CoV-2 replication both in (sub)micromolar range. Zinc pyrithione 1a is a well-established, commercially available antimicrobial agent and was therefore selected for further evaluation of its SARS-CoV-2 entry and replication inhibition in an ex vivo system derived from primary human lung tissue. Our results suggest that zinc pyrithione complex 1a provides a multitarget approach to combat SARS-CoV-2 and should be considered for repurposing as a potential therapeutic against the insidious COVID-19 disease.Featured imageIn our study, we show that zinc pyrithione holds immense potential for the development of a possible out-patient treatment for SARS-CoV-2 due to its inhibition of viral entry and replication.
Published: 2022
Full Text: View/download PDF

11. Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients

Author: Florentino Villanego, Auxiliadora Mazuecos, Beatriz Cubillo, M José Merino, Inmaculada Poveda, Isabel M Saura, Óscar Segurado, Leónidas Cruzado, Myriam Eady, Sofía Zárraga, M José Aladrén, Sheila Cabello, Verónica López, Esther González, Inmaculada Lorenzo, Jordi Espí-Reig, Constantino Fernández, July Osma, M Carmen Ruiz-Fuentes, Néstor Toapanta, Antonio Franco, Carla C Burballa, Miguel A Muñoz, Marta Crespo, Julio Pascual, Institut Català de la Salut, [Villanego F, Mazuecos A] Department of Nephrology, Hospital Universitario Puerta del Mar, Cádiz, Spain. [Cubillo B] Department of Nephrology, Hospital Clínico San Carlos, Madrid, Spain. [Merino MJ] Department of Nephrology, Hospital Universitario Juan Ramón Jiménez, Huelva, Spain. [Poveda I] Department of Nephrology, Hospital Universitario Torrecárdenas, Almería, Spain. [Saura IM] Department of Nephrology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. [Toapanta N] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Transplantation, immunosuppression, Anticossos monoclonals - Ús terapèutic, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], COVID-19, kidney transplantation, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], terapéutica::tratamiento de reemplazo renal::trasplante de riñón [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Other subheadings::Other subheadings::/drug therapy [Other subheadings], mortality, COVID-19 (Malaltia) - Tractament, Nephrology, Therapeutics::Renal Replacement Therapy::Kidney Transplantation [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], monoclonal antibodies, Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal [CHEMICALS AND DRUGS], Ronyons - Trasplantació - Complicacions, aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales [COMPUESTOS QUÍMICOS Y DROGAS]
Abstract: Background Sotrovimab is a neutralizing monoclonal antibody (mAb) that seems to remain active against recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The evidence on its use in kidney transplant (KT) recipients, however, is limited. Methods We performed a multicenter, retrospective cohort study of 82 KT patients with SARS-CoV-2 infection {coronavirus disease 2019 [COVID-19]} treated with sotrovimab. Results Median age was 63 years. Diabetes was present in 43.9% of patients, and obesity in 32.9% of patients; 48.8% of patients had an estimated glomerular filtration rate under 30 mL/minute/1.73 m2. Additional anti–COVID-19 therapies were administered to 56 patients, especially intravenous steroids (65.9%). Sotrovimab was administered early ( Conclusions Sotrovimab had an excellent safety profile, even in high-comorbidity patients and advanced chronic kidney disease stages. Earlier administration could prevent progression to severe disease, while clinical outcomes were poor in patients treated later. Larger controlled studies enrolling KT recipients are warranted to elucidate the true efficacy of monoclonal antibody therapies.
Published: 2022

12. PriTec-COVID-19: una eina per a la priorització de la innovació

Author: Torres-López, Marta, Reixach-Espaulella, Elisenda, Magem, David, Giménez-García, Emmanuel, Andrés, Erik, Espallargues-Carreras, Mireia, [Torres M] Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Reixach E, Andrés E] Fundació TIC Salut i Social, Barcelona, Spain. [Magem D] Gerència de Planificació Operativa i Avaluació, Àrea Assistencial, Servei Català de la Salut (CatSalut), Generalitat de Catalunya, Barcelona, Spain. [Gimenez E] Unitat de Suport a la Decisió, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Barcelona, Spain. [Espallargues M] Direcció Científica i de Qualitat, Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQUAS), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, Spain, and Departament de Salut
Subjects: Medicina - Innovacions, COVID-19 (Malaltia) - Tractament, Tecnologia mèdica - Avaluació, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Health Sciences, Technology, and Innovation Management::Scientific and Technical Activities::Projects::Technological Development and Innovation Projects [SCIENCE AND HEALTH], gestión de ciencia, tecnología e innovación en salud::ciencia, tecnología y sociedad::evaluación de tecnologías biomédicas [CIENCIA Y SALUD], gestión de ciencia, tecnología e innovación en salud::actividades científicas y tecnológicas::proyectos::proyectos de desarrollo tecnológico e innovación [CIENCIA Y SALUD], Health Sciences, Technology, and Innovation Management::Science, Technology and Society::Technology Assessment, Biomedical [SCIENCE AND HEALTH]
Abstract: Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Innovació tecnològica; Priorització Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Innovación tecnológica; Priorización Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Technological innovation; Prioritization La pandèmia global de COVID-19 ha posat de manifest, entre d’altres, la necessitat d’adoptar solucions tecnològiques innovadores de forma ràpida i eficient. Un grup de treball interinstitucional, organitzat i impulsat per l’Agència de Qualitat i Avaluació Sanitàries (AQuAS) i la Fundació TIC Salut i Social (FTSS) per facilitar i accelerar l’avaluació i l’adopció de la innovació adreçada a buscar solucions per a la crisi de la COVID-19, va identificar la necessitat de disposar d’un sistema de mesura a fi de de prioritzar-la. Per donar resposta a aquesta necessitat, un subgrup de treball format per cinc professionals multidisciplinaris va desenvolupar una nova eina a partir de l’eina de priorització PriTec. Per fer-ho, els ítems PriTec originals van ser revisats i alineats amb les necessitats de la pandèmia de COVID-19, en el context de la innovació. L'eina modificada es va provar mitjançant cicles de puntuació de diverses tecnologies emergents i innovadores. Un cop definits els seus dominis i ítems, cinc nous avaluadors van valorar tres de les iniciatives puntuades anteriorment. La concordança entre les puntuacions dels avaluadors es va estimar calculant el coeficient de correlació intra-classe. L’eina resultant conté 20 ítems, a més d’un de cribratge inicial, distribuïts en 5 dominis: 1) Malaltia o condició clínica; 2) Resultats comparats; 3) Impacte econòmic; 4) Factibilitat de la implementació; 5) Aspectes relatius a la difusió. La seva valoració permet obtenir una puntuació global per a cada proposta d’innovació, i s’ha obtingut una bona correlació entre avaluadors. Tot i que caldria aprofundir i completar la seva validació, l’eina permetria prioritzar tecnologies de forma ràpida i senzilla, tenint en compte tots els aspectes rellevants per a la seva avaluació i eventual adopció. PriTec-COVID-19 és adreçada a la priorització de l’avaluació de tecnologies per fer front a la crisi produïda per la COVID-19, però permet ser adaptada davant de futures necessitats emergents. La pandemia global de COVID-19 ha puesto de manifiesto, entre otras, la necesidad de adoptar soluciones tecnológicas innovadoras de forma rápida y eficiente. Un grupo de trabajo interinstitucional, organizado e impulsado por la Agència de Qualitat i Avaluació Sanitàries (AQuAS) y la Fundació TIC Salut i Social (FTSS) para facilitar y acelerar la evaluación y la adopción de la innovación dirigida a buscar soluciones para la crisis de la COVID-19, identificó la necesidad de disponer de un sistema de medida para priorizarla. Para dar respuesta a esta necesidad, un subgrupo de trabajo formado por cinco profesionales multidisciplinares desarrolló una nueva herramienta a partir de la herramienta de priorización PriTec. Para ello, los ítems PriTec originales fueron revisados y alineados con las necesidades de la pandemia de COVID-19, en el contexto de la innovación. La herramienta modificada se probó mediante ciclos de puntuación de diversas tecnologías emergentes e innovadoras. Una vez definidos sus dominios e ítems, cinco nuevos evaluadores valoraron tres de las iniciativas puntuadas anteriormente. La concordancia entre las puntuaciones de los evaluadores se estimó calculando el coeficiente de correlación intra-clase. La herramienta resultante contiene 20 ítems, además de uno de cribado inicial, distribuidos en 5 dominios: 1) Enfermedad o condición clínica; 2) Resultados comparados; 3) Impacto económico; 4) Factibilidad de la implementación; 5) Aspectos relativos a la difusión. Su valoración permite obtener una puntuación global para cada propuesta de innovación, obteniendo una buena correlación entre evaluadores. Aunque se debería profundizar y completar su validación, la herramienta permitiría priorizar tecnologías de forma rápida y sencilla, teniendo en cuenta todos los aspectos relevantes para su evaluación y eventual adopción. PriTec-COVID-19 está dirigida a la priorización de tecnologías para hacer frente a la crisis producida por la COVID-19, pero permite ser adaptada ante futuras necesidades emergentes The global COVID-19 pandemic has highlighted, among others, the need to adopt innovative technological solutions quickly and efficiently. An inter-institutional working group, organized and promoted by the Agència de Qualitat i Avaluació Sanitàries (AQuAS) and the Fundació TIC Salut i Social (FTSS) to facilitate and accelerate the evaluation and adoption of innovation aimed at finding solutions for the COVID-19 crisis, has identified the need for a measurement system to prioritize it. To address this need, a working subgroup of five multidisciplinary professionals has developed a new tool based on the PriTec prioritization tool. To do this, they reviewed and aligned the original PriTec items with the needs of the COVID-19 pandemic, in the context of innovation. The modified tool was tested through scoring cycles of various emerging and innovative technologies. Once defined its domains and items, five new reviewers rated three of the previously rated initiatives. The concordance between the evaluators' scores was estimated by calculating the intra-class correlation coefficient. The resulting tool contains 20 items, plus another one corresponding to an initial screening, distributed in 5 domains: 1) Illness or clinical condition; 2) Comparative results; 3) Economic impact; 4) Feasibility of implementation; 5) Aspects related to dissemination. The tool makes it possible to obtain an overall score for each innovation proposal, with a good correlation between evaluators. Although it would be necessary to complete and refine its validation, the tool would allow to prioritize technologies quickly and easily, taking into account all the relevant aspects for its evaluation and eventual adoption. PriTec-COVID-19 aims at prioritizing technologies to deal with the crisis caused by COVID-19 and allows its adaptation to future emerging needs.
Published: 2021

13. COVID-19 i ozonoteràpia: resposta ràpida

Author: Vivanco-Hidalgo, Rosa M., Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQUAS), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain, and Departament de Salut
Subjects: compuestos inorgánicos::gases::oxígeno::ozono [COMPUESTOS QUÍMICOS Y DROGAS], Ozó - Ús terapéutic, COVID-19 (Malaltia) - Tractament, Otros calificadores::/uso terapéutico [Otros calificadores], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Other subheadings::/therapy [Other subheadings], Other subheadings::/therapeutic use [Other subheadings], Inorganic Chemicals::Gases::Oxygen::Ozone [CHEMICALS AND DRUGS], Otros calificadores::/terapia [Otros calificadores]
Abstract: Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Ozonoteràpia Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Ozonoterapia Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Ozone therapy L'objectiu d'aquesta publicació és descriure l’evidència disponible sobre l’ozonoteràpia per al tractament per la infecció aguda SARSCov-2/COVID-19.
Published: 2021

14. Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19

Author: Mireia López-Corbeto, Antonio Gomez, Richard M. Myers, Iván Rodríguez-Núñez, Irene Bonafonte-Pardàs, Sergio H Martínez-Mateu, Antonio Julià, María López-Lasanta, Jordi Lladós, S. Marsal, Institut Català de la Salut, [Julià A, Bonafonte-Pardàs I, Gómez A, López-Lasanta M, López-Corbeto M, Martínez-Mateu SH, Lladós J, Marsal S] Grup de Recerca en Reumatologia, Servei de Reumatologia, Vall d’Hebron Hospital Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Male, medicine.medical_treatment, Inflammatory diseases, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Severity of Illness Index, Arthritis, Rheumatoid, 0302 clinical medicine, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Medicine, RNA-Seq, 0303 health sciences, Multidisciplinary, medicine.diagnostic_test, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Middle Aged, Up-Regulation, enfermedades musculoesqueléticas::artropatías::artritis::artritis reumatoide [ENFERMEDADES], 3. Good health, Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents [CHEMICALS AND DRUGS], Observational Studies as Topic, Cytokine release syndrome, Cytokine, 030220 oncology & carcinogenesis, Cohort, B7-1 Antigen, Female, Single-Cell Analysis, Cytokine Release Syndrome, Bronchoalveolar Lavage Fluid, Musculoskeletal Diseases::Joint Diseases::Arthritis::Arthritis, Rheumatoid [DISEASES], Immunosuppressive Agents, Signal Transduction, medicine.drug, China, Science, Artritis reumatoide - Tractament, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Article, Proinflammatory cytokine, Abatacept, 03 medical and health sciences, Therapeutic approach, COVID-19 (Malaltia) - Tractament, Target identification, Humans, Aged, 030304 developmental biology, SARS-CoV-2, business.industry, COVID-19, Medicaments immunosupressors - Ús terapèutic, medicine.disease, United States, COVID-19 Drug Treatment, Bronchoalveolar lavage, Viral infection, Spain, Immunology, B7-2 Antigen, business, Cytokine storm, acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::factores inmunitarios::inmunosupresores [COMPUESTOS QUÍMICOS Y DROGAS]
Abstract: Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Malalties inflamatòries; Identificació de l'objectiu; Infecció viral Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Enfermedades inflamatorias; Identificación del objetivo; Infección viral Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflammatory diseases; Target identification; Viral infection An excessive immune response known as cytokine storm is the hallmark of severe COVID-19. The cause of this cytokine rampage is yet not known. Based on recent epidemiological evidence, we hypothesized that CD80/86 signaling is essential for this hyperinflammation, and that blocking this proinflammatory axis could be an effective therapeutic approach to protect against severe COVID-19. Here we provide exploratory evidence that abatacept, a drug that blocks CD80/86 co-stimulation, produces changes at the systemic level that are highly antagonistic of the proinflammatory processes elicited by COVID-19. Using RNA-seq from blood samples from a longitudinal cohort of n = 38 rheumatic patients treated with abatacept, we determined the immunological processes that are significantly regulated by this treatment. We then analyzed available blood RNA-seq from two COVID19 patient cohorts, a very early cohort from the epicenter of the pandemic in China (n = 3 COVID-19 cases and n = 3 controls), and a recent and larger cohort from the USA (n = 49 severe and n = 51 mild COVD-19 patients). We found a highly significant antagonism between SARS-CoV-2 infection and COVID-19 severity with the systemic response to abatacept. Analysis of previous single-cell RNA-seq data from bronchoalveolar lavage fluid from mild and severe COVID-19 patients and controls, reinforce the implication of the CD80/86 proinflammatory axis. Our functional results further support abatacept as a candidate therapeutic approach to prevent severe COVID-19. The PACTABA project was funded Bristol-Myers Squibb. We thank all participants from the PACTABA study for their collaboration. AJ and SM are supported by the DoCTIS project funded by the European Union’s H2020 programme (Grant #848028). This work was supported by funds from the Vall d’Hebron Hospital Research Institute and from IMIDomics S.L. We thank Dr Ariel Jaitovich (Albany Medical Centre, USA) for providing additional clinical data on the late COVID-19 cohort.
Published: 2021

15. Algoritmes de tractament dels pacients amb infecció per SARS-CoV-2

Author: Comissió Assessora per al Tractament de la Infecció per SARS-CoV-2 and Departament de Salut
Subjects: Infections::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Pneumònia - Tractament, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Otros calificadores::/diagnóstico [Otros calificadores], Respiratory Tract Diseases::Respiratory Tract Diseases::Respiratory Tract Infections::Pneumonia [DISEASES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Infeccions per coronavirus, Coronavirus - Tractament, COVID-19 (Malaltia) - Tractament, Other subheadings::/diagnosis [Other subheadings], enfermedades respiratorias::enfermedades respiratorias::infecciones del tracto respiratorio::neumonía [ENFERMEDADES], Infections::Respiratory Tract Infections::Pneumonia [DISEASES], Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores]
Abstract: Coronavirus SARS-Cov-2; COVID-19; 2019-nCoV; Algoritme; Detecció; Tractament; Atenció primària; Hospital; Residència Coronavirus SARS-Cov-2; COVID-19; 2019-nCoV; Algoritmo; Detección; Tratamiento; Atención primaria; Hospital; Residencia Coronavirus SARS-Cov-2; COVID-19; 2019-nCoV; Algorithm; Detection; Treatment; Primary care; Hospital; Home Aquest document inclou una síntesi breu en format d’algorisme del document Tractament farmacològics de la infecció per SARS-CoV-2 del CatSalut. La manca d’evidències requereix una acurada valoració dels beneficis potencials, encara desconeguts, i dels riscs associats als tractaments farmacològics, sempre considerant les característiques del pacient en quant a morbiditat de base i factors de risc. Este documento incluye una breve síntesis en formato de algoritmo del documento Tratamiento farmacológicos de la infección por SARS-CoV-2 del CatSalut. La falta de evidencias requiere una cuidadosa valoración de los beneficios potenciales, aún desconocidos, y de los riesgos asociados a los tratamientos farmacológicos, siempre considerando las características del paciente en cuanto a morbilidad de base y factores de riesgo. This document includes a brief summary in algorithmic format of the document: Pharmacological treatment of CatSalut SARS-CoV-2 infection. The lack of evidence requires a careful assessment of the potential benefits, still unknown, and the risks associated with pharmacological treatments, always considering the patient's characteristics in terms of baseline morbidity and risk factors.
Published: 2021

16. [Spanish consensus document on diagnosis, stabilisation and treatment of pediatric multisystem inflammatory syndrome related to SARS-CoV-2 (SIM-PedS)]

Author: García-Salido, Alberto, Antón, Jordi, Martínez-Pajares, José David, Giralt Garcia, Gemma, Gómez Cortés, Borja, Tagarro, Alfredo, Grupo de trabajo de la Asociación Española de Pediatría para el Síndrome Inflamatorio Multisistémico Pediátrico vinculado a SARS-CoV-2, Miembros del Grupo de trabajo de la Asociación Española de Pediatría para el Síndrome Inflamatorio Multisistémico Pediátrico vinculado a SARS-CoV-2, Belda Hofheinz, Sylvia, Calvo Penadés, Inmaculada, de Carlos Vicente, Juan Carlos, Grasa Lozano, Carlos Daniel, Hernández Bou, Susanna, Pino Ramírez, Rosa M, Núñez Cuadros, Esmeralda, Pérez-Lescure Picarzo, Javier, Saavedra Lozano, Jesús, Salas-Mera, Diana, Villalobos Pinto, Enrique, Institut Català de la Salut, [García-Salido A] Sociedad Española de Cuidados Intensivos Pediátricos (SECIP). Cuidados Intensivos Pediátricos, Hospital Infantil Universitario Niño Jesús, Madrid, Spain. [Antón J] Sociedad Española de Reumatología pediátrica (SERPE). Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu (IRSJD), Barcelona, Spain. [Martínez-Pajares JD] Sociedad Española de Pediatría Hospitalaria (SEPHO). Unidad de Pediatría, Hospital de Antequera, Área Sanitaria Norte de Málaga, Málaga, Spain. [Giralt Garcia G] Sociedad Española de Cardiología Pediátrica y Cardiopatías Congénitas (SECPCC). Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Gómez Cortés B] Sociedad Española de Urgencias de Pediatría (SEUP). Servicio de Urgencias de Pediatría. Hospital Universitario Cruces, Barakaldo, Spain. [Tagarro A] Sociedad Española de Infectología Pediátrica (SEIP). Servicio de Pediatría, Hospital Universitario Infanta Sofía, Unidad Pediátrica de Investigación y Ensayos Clínicos (UPIC), Instituto de Investigación Sanitaria Hospital 12 de Octubre (IMAS12), Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Otros calificadores::/diagnóstico [Otros calificadores], Multisystem inflammatory syndrome, Pediatrics, RJ1-570, 03 medical and health sciences, 0302 clinical medicine, COVID-19 (Malaltia) - Tractament, 030225 pediatrics, Other subheadings::/diagnosis [Other subheadings], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Humans, Pediatrics, Perinatology, and Child Health, skin and connective tissue diseases, afecciones patológicas, signos y síntomas::procesos patológicos::inflamación::síndrome de respuesta inflamatoria sistémica [ENFERMEDADES], Child, Otros calificadores::/terapia [Otros calificadores], Pediatria intensiva, SARS-CoV-2, fungi, Pediatría, Síndrome inflamatorio multisistémico, COVID-19, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Paediatrics, Other subheadings::/therapy [Other subheadings], Systemic Inflammatory Response Syndrome, Asociación Española De Pediatría, body regions, Pediatrics, Perinatology and Child Health, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation::Systemic Inflammatory Response Syndrome [DISEASES], Inflamació - Tractament, Algorithms
Abstract: Síndrome inflamatori multisistèmic; Pediatria; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV Síndrome inflamatorio multisistémico; Pediatría; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV Multisystem inflammatory syndrome; Paediatrics; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV Se ha descrito un nuevo síndrome inflamatorio multisistémico pediátrico vinculado a SARS-CoV-2. Este cuadro presenta una expresividad clínica variable y se asocia a infección activa o reciente por SARS-CoV-2. En este documento se revisa la literatura existente por parte de un grupo multidisciplinar de especialistas pediátricos. Posteriormente, se realizan recomendaciones sobre estabilización, diagnóstico y tratamiento de este síndrome. A new paediatric multisystem inflammatory syndrome, linked to SARS-CoV-2, has been described. The clinical picture is variable and is associated with an active or recent infection due to SARS-CoV-2. A review of the existing literature by a multidisciplinary group of paediatric specialists is presented in this document. Later, they make recommendations on the stabilisation, diagnosis, and treatment of this syndrome.
Published: 2021
Full Text: View/download PDF

17. Recull de l’evidència del tractament farmacològic de la infecció per SARS-CoV-2

Author: Departament de Salut
Subjects: COVID-19 (Malaltia) - Tractament, Medicaments - Assaigs clínics, Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores], Health Occupations::Evidence-Based Practice::Evidence-Based Medicine [DISCIPLINES AND OCCUPATIONS], Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics::Clinical Studies as Topic::Clinical Trials as Topic [HEALTH CARE], Infecciones::Virosis::Infecciones por Virus ARN::Infecciones por Nidovirales::Infecciones por Coronaviridae::Infecciones por Coronavirus [ENFERMEDADES], Infections::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Medicaments - Administració, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Empleos en Salud::Práctica Clínica Basada en la Evidencia::Medicina Basada en la Evidencia [DISCIPLINAS Y OCUPACIONES], calidad, acceso y evaluación de la atención sanitaria::calidad de la atención sanitaria::mecanismos de evaluación de la atención sanitaria::características de los estudios epidemiológicos::estudios clínicos como asunto::ensayos clínicos como asunto [ATENCIÓN DE SALUD]
Published: 2021

18. Use and safety of remdesivir in kidney transplant recipients with COVID-19

Author: Maria Luisa Martin, Cristina Canal, Carlos Arias-Cabrales, Antonio Franco, Francesc Moreso, Isabel María Saura, Luis Sanchez-Cámara, Sofía Zárraga, Sheila Cabello Pelegrin, Julio Pascual, Emilio Sánchez-Álvarez, Inmaculada Lorenzo, Anna Buxeda, Raquel Santana-Estupiñán, Edoardo Melilli, María José Aladrén, Esperanza Moral Berrio, Judit Cacho, Marta Crespo, Orlando Siverio, Auxiliadora Mazuecos, José Portolés, Verónica López, Elena González-García, Paloma L Martin-Moreno, Iñigo Moina, María José Pérez-Sáez, Cristina Galeano, María del Carmen Ruiz-Fuentes, Institut Català de la Salut, [Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ] Department of Nephrology, Hospital del Mar, Institute Mar for Medical Research (IMIM), Red de Investigación Renal (REDinREN) (RD16/0009/0013), Barcelona, Spain. [Cacho J] Department of Nephrology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Cabello Pelegrin S] Department of Nephrology, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Melilli E] Department of Nephrology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain. [Moreso F] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: medicine.medical_specialty, enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::lesión renal aguda [ENFERMEDADES], medicine.medical_treatment, Trasplantament renal, Remdesivir, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Injury, Other subheadings::Other subheadings::/drug therapy [Other subheadings], law.invention, Kidney transplantation, SARS-CoV2l, Randomized controlled trial, COVID-19 (Malaltia) - Tractament, law, Clinical Research, Internal medicine, medicine, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Adverse effect, business.industry, SARS-CoV-2, Acute kidney injury, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Immunosuppression, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], medicine.disease, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Acute Kidney Injury [DISEASES], Discontinuation, Insuficiència renal aguda, Nephrology, SARS-CoV2, Cohort, Avaluació de resultats (Assistència sanitària), Acute kidney, business, Cohort study
Abstract: Introduction:Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time torecovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acutekidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidneytransplant recipients.Methods:We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treatedwith remdesivir. Outcomes and safety were assessed.Results:Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) requiredmechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged$65 years(45% vs. 3.2% in younger patients). Acute kidneyinjury was present in 27.7% of patients, but wasdiagnosed in 50% before treatment. No patients required remdesivir discontinuation because ofadverse events. We did notfind significant hepatoxicity or systemicsymptoms resulting from thedrug. Conclusion:In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renaland hepatic toxicity, but randomized trials are needed to assess its efficacy. The authors are indebted to the many physicians andnurses who take care of these patients and are facing theCOVID-19 pandemic in our country. This research wassupported by Rio Hortega contract CM19/00004 (ISCIII)(AB), and RD16/0009/0013 (ISCIII FEDER RedinRen). MJP-S is supported by a Spanish Society of Transplantscholarship
Published: 2021

19. Long-term follow-up of recovered MPN patients with COVID-19

Author: Barbui, Tiziano, Iurlo, Alessandra, Masciulli, Arianna, Carobbio, Alessandra, Ghirardi, Arianna, Rossi, Giuseppe, Harrison, Claire, Alvarez-Larran, Alberto, Elli, Elena María, Kiladjian, Jean-Jaques, Gasior Kabat, Mercedes, Marin Sanchez, Alberto, Palandri, Francesca, Andrade-Campos, Marcio Miguel, Vannucchi, Alessandro Maria, Carreño-Tarragona, Gonzalo, Papadopoulos, Petros, Quiroz Cervantes, Keina, Foncillas, Maria Angeles, Fox, Maria Laura, Sagues Serrano, Miguel, Rumi, Elisa, Osorio, Santiago, Benevolo, Giulia, Patriarca, Andrea, Navas Elorza, Begoña, Garcia-Gutierrez, Valentín, Magro Mazo, Elena, Lunghi, Francesca, Bonifacio, Massimiliano, De Stefano, Valerio, Hernandez-Boluda, Juan Carlos, Lopez Abadia, Emma, Angona, Anna, Xicoy Cirici, Blanca, Ruggeri, Marco, Koschmieder, Steffen, Sobas, Marta Anna, Cuevas, Beatriz, Cattaneo, Daniele, Daffini, Rosa, Bellini, Marta, Curto-Garcia, Natalia, Garrote, Marta, Cavalca, Fabrizio, Benajiba, Lina, Bellosillo Paricio, Beatriz, Guglielmelli, Paola, Borsani, O., Betti, Silvia, Salmoiraghi, Silvia, Rambaldi, Alessandro, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Barbui T, Masciulli A, Carobbio A, Ghirardi A] FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy. [Iurlo A] Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. [Rossi G] Spedali Civili, Brescia, Italy. [Fox ML] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Myeloid, Male, Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores], Myeloproliferative disease, Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders [DISEASES], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Otros calificadores::/terapia [Otros calificadores], RC254-282, Aged, 80 and over, Leukemia, Lymphoma, Non-Hodgkin, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Hematology, Middle Aged, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Treatment Outcome, Oncology, Infectious diseases, Female, medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Long term follow up, MEDLINE, enfermedades hematológicas y linfáticas::enfermedades hematológicas::enfermedades de la médula ósea::trastornos mieloproliferativos [ENFERMEDADES], Myeloproliferative Disorders, COVID-19 (Malaltia) - Tractament, Internal medicine, Correspondence, COVID-19 - complications, medicine, Humans, Aged, business.industry, SARS-CoV-2, Trastorns mieloproliferatius - Complicacions, COVID-19, COVID-19 - mortality, Other subheadings::/therapy [Other subheadings], medicine.disease, Lymphoma, Avaluació de resultats (Assistència sanitària), business, Other subheadings::Other subheadings::/complications [Other subheadings], Follow-Up Studies
Abstract: Blood cancer journal 11(6), 115 (2021). doi:10.1038/s41408-021-00509-0, Published by Nature Publishing Group, London [u.a.]
Published: 2021

20. Protocol d’atenció a les persones amb infecció per SARS-CoV-2 a l’atenció primària

Author: Departament de Salut
Subjects: atención a la salud (salud pública)::niveles de atención a la salud::atención a la salud (salud pública)::atención primaria de la salud [SALUD PÚBLICA], COVID-19 (Malaltia) - Tractament, Atenció primària, vigilancia sanitaria de los servicios de salud::prestación sanitaria::asistencia al paciente::terapéutica::protocolos clínicos [VIGILANCIA SANITARIA], Health Care (Public Health)::Health Care Levels::Health Care (Public Health)::Primary Health Care [PUBLIC HEALTH], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Protocols clínics, Health Surveillance of Health Services::Delivery of Health Care::Patient Care::Therapeutics::Clinical Protocols [HEALTH SURVEILLANCE]
Abstract: Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Atenció primària; Procediments Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Atención primaria; Procedimientos Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Primary care; Procedures Aquest document és una proposta d’atenció a la Covid‐19 a l’AP, amb la idea que cada EAP l’adapti segons les seves circumstàncies. Ha estat elaborat a partir d’una revisió de l'abordatge del pacient amb infecció per SARS‐CoV‐2.
Published: 2020

21. Tractament farmacològic de la infecció per SARS-CoV-2

Author: Comissió Assessora per al Tractament Farmacològic de la Infecció per SARS-CoV-2 and Departament de Salut
Subjects: COVID-19 (Malaltia) - Tractament, Infections::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Medicaments - Administració, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Infeccions per coronavirus, Coronavirus - Tractament, Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores]
Abstract: Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Pacients adults; Tractament farmacològic; SISCAT; Assaigs clínics Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Pacientes adultos; Tratamiento farmacológico; SISCAT; Ensayos clínicos Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Adult patients; Pharmacological treatment; SISCAT; Clinical trials L’objectiu d’aquest document és resumir les recomanacions per al maneig i tractament farmacològic dels pacients amb infecció per coronavirus SARS-CoV-2 i fer-ne una actualització freqüent en base a l’aparició de novetats científiques i tenint en compte el context d’incertesa terapèutica de la malaltia. Així mateix, també s’inclou informació pràctica pel maneig dels medicaments per als professionals sanitaris i les notificacions relacionades amb els medicaments que s’han realitzat en el context d’aquesta epidèmia.
Published: 2020

22. Recull de l’evidència del tractament farmacològic de la infecció per SARS-CoV-2

Author: Comissió Assessora per al Tractament Farmacològic de la Infecció per SARS-CoV-2 and Departament de Salut
Subjects: Infections::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores], profesiones sanitarias::práctica basada en pruebas::medicina basada en datos científicos [DISCIPLINAS Y OCUPACIONES], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Clinical Studies as Topic::Clinical Trials as Topic [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Health Occupations::Evidence-Based Practice::Evidence-Based Medicine [DISCIPLINES AND OCCUPATIONS], Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics::Clinical Studies as Topic::Clinical Trials as Topic [HEALTH CARE], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Infeccions per coronavirus, calidad, acceso y evaluación de la atención sanitaria::calidad de la atención sanitaria::mecanismos de evaluación de la atención sanitaria::características de los estudios epidemiológicos::estudios clínicos como asunto::ensayos clínicos como asunto [ATENCIÓN DE SALUD], Coronavirus - Tractament, COVID-19 (Malaltia) - Tractament, Técnicas de Investigación::Métodos Epidemiológicos::Características de Estudios Epidemiológicos::Estudios Clínicos como Asunto::Ensayos Clínicos como Asunto [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Medicaments - Assaigs clínics, Medicaments - Administració, Empleos en Salud::Práctica Clínica Basada en la Evidencia::Medicina Basada en la Evidencia [DISCIPLINAS Y OCUPACIONES]
Abstract: Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Evidència científica; Tractament farmacològic Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Evidencia científica; Tratamiento farmacológico Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Scientific evidence; Pharmacological treatment L’objectiu d’aquest document és recollir i resumir les evidències científiques i clíniques actuals i les noves que es vagin generant sobre el tractament farmacològic de la infecció per SARSCoV-2.
Published: 2020

23. Algoritme de seguiment dels pacients COVID-19 a l’AP

Author: Departament de Salut
Subjects: atención a la salud (salud pública)::niveles de atención a la salud::atención a la salud (salud pública)::atención primaria de la salud [SALUD PÚBLICA], Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores], terapéutica::protocolos clínicos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Pharmaceutical Preparations [CHEMICALS AND DRUGS], Therapeutics::Clinical Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Other subheadings::/diagnosis [Other subheadings], Otros calificadores::/diagnóstico [Otros calificadores], preparados farmacéuticos [COMPUESTOS QUÍMICOS Y DROGAS], COVID-19 (Malaltia) - Tractament, Atenció primària, Health Care (Public Health)::Health Care Levels::Health Care (Public Health)::Primary Health Care [PUBLIC HEALTH], Other subheadings::Other subheadings::/administration & dosage [Other subheadings], COVID-19 (Malaltia) - Diagnòstic, Infections::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Medicaments - Administració
Abstract: Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Algoritme; Diagnòstic; Tractament farmacològic; Atenció primària Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Algoritmo; Diagnóstico; Tratamiento farmacológico; Atención primaria Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Algorithm; Diagnosis; Drug therapy; Primary care Document que presenta l'algoritme d'actuació davant els pacients diagnosticats de coronavirus COVID-19 a l'atenció primària.
Published: 2020

24. Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge

Author: Tomasz Skirecki, Evangelos J. Giamarellos-Bourboulis, Matthijs Kox, F. M. Brunkhorst, Gunnar Lachmann, Stefanie B. Flohé, Ignacio Martin-Loeches, Marcin F. Osuchowski, Jean-Marc Cavaillon, Antoni Torres, Fabienne Venet, Alberto García-Salido, Massimo Girardis, Ignacio Rubio, Joerg C. Schefold, Sebastian Weis, Florian Uhle, André Scherag, Sara Cajander, Ricard Ferrer, Thibaud Spinetti, Mihai G. Netea, Martin Sebastian Winkler, Institut Català de la Salut, [Winkler MS] Department of Anesthesiology, Emergency and Intensive Care Medicine, University of Göttingen, Göttingen, Göttingen, Germany. [Skirecki T] Laboratory of Flow Cytometry, Centre of Postgraduate Medical Education, Warsaw, Poland. [Brunkhorst FM] Dept. of Anesthesiology and Intensive Care Medicine & Center for Sepsis Control and Care (CSCC), Jena University Hospital-Friedrich Schiller University, Jena, Germany. Center for Clinical Studies, Jena University Hospital, Jena, Germany. [Cajander S] Department of Infectious Diseases, Faculty of Medicine and Health, Örebro University, Sweden. [Cavaillon JM] French National Research Agency (ANR), Paris, France. [Ferrer R] Servei de Cures Intensives i Xoc, Grup de Recerca en Disfunció Orgànica i Reanimació, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomedica En Red-Enfermedades Respiratorias, Instituto de salud Carlos III (ISCIII), Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: 0301 basic medicine, Medicine (General), Medizin, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Review, Pre-clinical research, Vacunes, Mice, 0302 clinical medicine, Animal model, Clinical trial, COVID-19, Pandemic, Vaccine, Cricetinae, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Clinical treatment, Otros calificadores::/terapia [Otros calificadores], mezclas complejas::productos biológicos::vacunas [COMPUESTOS QUÍMICOS Y DROGAS], Clinical Trials as Topic, Age Factors, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], General Medicine, 3. Good health, 030220 oncology & carcinogenesis, Medicine, Primates, medicine.medical_specialty, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 610 Medicine & health, Antiviral Agents, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, R5-920, COVID-19 (Malaltia) - Tractament, medicine, Animals, Humans, Medical history, Intensive care medicine, Complex Mixtures::Biological Products::Vaccines [CHEMICALS AND DRUGS], SARS-CoV-2, business.industry, Ferrets, Other subheadings::/therapy [Other subheadings], COVID-19 Drug Treatment, Disease Models, Animal, 030104 developmental biology, Clinical research, Clinical evidence, Mutation, Models animals en la investigació, Investigative Techniques::Models, Animal::Investigative Techniques::Disease Models, Animal [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], técnicas de investigación::modelos animales::técnicas de investigación::modelos de enfermedad en animales [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], business
Abstract: Model animal; COVID-19; Recerca preclínica Modelo animal; COVID-19; Investigación preclínica Animal model; COVID-19; Pre-clinical research Many milestones in medical history rest on animal modeling of human diseases. The SARS-CoV-2 pandemic has evoked a tremendous investigative effort primarily centered on clinical studies. However, several animal SARS-CoV-2/COVID-19 models have been developed and pre-clinical findings aimed at supporting clinical evidence rapidly emerge. In this review, we characterize the existing animal models exposing their relevance and limitations as well as outline their utility in COVID-19 drug and vaccine development. Concurrently, we summarize the status of clinical trial research and discuss the novel tactics utilized in the largest multi-center trials aiming to accelerate generation of reliable results that may subsequently shape COVID-19 clinical treatment practices. We also highlight areas of improvement for animal studies in order to elevate their translational utility. In pandemics, to optimize the use of strained resources in a short time-frame, optimizing and strengthening the synergy between the preclinical and clinical domains is pivotal.
Published: 2021

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

24 results on '"COVID-19 (Malaltia) - Tractament"'

1. Oxygen Consumption with High-Flow Nasal Oxygen versus Mechanical Ventilation- An International Multicenter Observational Study in COVID-19 Patients (PROXY-COVID)

2. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

3. Dextran sulfate from Leuconostoc mesenteroides B512F exerts potent antiviral activity against SARS-CoV-2 in vitro and in vivo

4. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial

5. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies

6. Recomanacions per a l’inici i el seguiment del tractament amb Paxlovid® per a pacients amb COVID-19 lleu-moderada amb risc alt de progressar a formes greus

7. Convalescent plasma for SARS-CoV-2 infection: win or learn

8. Cytokine Hemoadsorption as Rescue Therapy for Critically Ill Patients With SARS-CoV-2 Pneumonia With Severe Respiratory Failure and Hypercytokinemia

9. Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

10. Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication

11. Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients

12. PriTec-COVID-19: una eina per a la priorització de la innovació

13. COVID-19 i ozonoteràpia: resposta ràpida

14. Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19

15. Algoritmes de tractament dels pacients amb infecció per SARS-CoV-2

16. [Spanish consensus document on diagnosis, stabilisation and treatment of pediatric multisystem inflammatory syndrome related to SARS-CoV-2 (SIM-PedS)]

17. Recull de l’evidència del tractament farmacològic de la infecció per SARS-CoV-2

18. Use and safety of remdesivir in kidney transplant recipients with COVID-19

19. Long-term follow-up of recovered MPN patients with COVID-19

20. Protocol d’atenció a les persones amb infecció per SARS-CoV-2 a l’atenció primària

21. Tractament farmacològic de la infecció per SARS-CoV-2

22. Recull de l’evidència del tractament farmacològic de la infecció per SARS-CoV-2

23. Algoritme de seguiment dels pacients COVID-19 a l’AP

24. Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

24 results on '"COVID-19 (Malaltia) - Tractament"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources